DNA-Repair Defects and Olaparib in Metastatic Prostat

New England Journal of Medicine
373, 1697-1708
DOI: 10.1056/nejmoa1506859

Citation Report

#	Article	IF	Citations
1	Convergent Science Physical Oncology. Convergent Science Physical Oncology, 2015, 1, 010201.	2.6	0
2	PARP inhibitors: a treatment option for AML?. Nature Medicine, 2015, 21, 1393-1394.	15.2	10
3	Molecular stratification and repair defects: revealing hidden treasures. Nature Reviews Clinical Oncology, 2015, 12, 683-683.	12.5	0
4	TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy. Oncotarget, 2016, 7, 68206-68228.	0.8	8
5	Targeting homologous recombination repair in cancer. , 2016, , 225-275.		3
6	Interrogating the Cancer Genome to Deliver More Precise Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e577-e583.	1.8	2
7	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 131-141.	1.8	19
8	Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e175-e184.	1.8	13
9	Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e259-e268.	1.8	14
10	Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers. Journal of Gastrointestinal Oncology, 2016, 7, 763-770.	0.6	1
11	Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?. Journal of Gastrointestinal Oncology, 2016, 7, 738-749.	0.6	14
12	Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas. PLoS ONE, 2016, 11, e0161438.	1.1	15
13	The In Vitro Stability of Circulating Tumour DNA. PLoS ONE, 2016, 11, e0168153.	1.1	18
14	Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1. Oncotarget, 2016, 7, 24326-24338.	0.8	33
15	Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix. Oncotarget, 2016, 7, 75379-75393.	0.8	27
16	DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics. Clinical Therapeutics, 2016, 38, 1577-1588.	1.1	27
17	A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling. Prostate, 2016, 76, 1303-1311.	1.2	21
18	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Clinical Cancer Research, 2016, 22, 4309-4321.	3.2	182

#	Article	IF	Citations
19	Implications of High Rates of Metastatic Prostate Cancer inBRCA2Mutation Carriers. Prostate, 2016, 76, 1135-1145.	1.2	9
20	The genetic classification of prostate cancer: whatâ€™s on the horizon?. Future Oncology, 2016, 12, 729-733.	1.1	5
21	Precision medicine for advanced prostate cancer. Current Opinion in Urology, 2016, 26, 231-239.	0.9	23
22	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453.	13.9	1,205
23	The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer. European Urology Focus, 2016, 2, 480-487.	1.6	15
24	The role of chemotherapy and new targeted agents in the management of primary prostate cancer. Journal of Clinical Urology, 2016, 9, 30-37.	0.1	2
25	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	2.0	82
26	Genetic predisposition to prostate cancer. British Medical Bulletin, 2016, 120, 75-89.	2.7	42
27	The â€˜Pushmi-Pullyuâ€™ of DNA REPAIR: Clinical Synthetic Lethality. Trends in Cancer, 2016, 2, 646-656.	3.8	18
28	Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer. Scientific Reports, 2016, 6, 3.	1.6	74
29	Targeting DNA Repair. Cancer Journal (Sudbury, Mass), 2016, 22, 353-356.	1.0	27
30	Genitourinary tumours in the targeted therapies era. Anti-Cancer Drugs, 2016, 27, 917-943.	0.7	8
31	DNA damage response as a therapeutic target in gynecological cancers. Current Opinion in Oncology, 2016, 28, 404-411.	1.1	8
32	Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. European Urology Focus, 2016, 2, 488-498.	1.6	38
34	PARP inhibitors: the race is on. British Journal of Cancer, 2016, 114, 713-715.	2.9	135
35	Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. European Urology, 2016, 70, 205-206.	0.9	1
36	Re: DNA-repair Defects and Olaparib in Metastatic Prostate Cancer. European Urology, 2016, 70, 204-205.	0.9	2
38	Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review. Molecular Cancer, 2016, 15, 41.	7.9	76

#	Article	IF	Citations
39	Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer and Prostatic Diseases, 2016, 19, 231-241.	2.0	142
40	Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis. Clinical Cancer Research, 2016, 22, 3132-3137.	3.2	28
41	Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. Clinical Therapeutics, 2016, 38, 1622-1635.	1.1	18
42	Anti-tumour activity of platinum compounds in advanced prostate cancerâ€"a systematic literature review. Annals of Oncology, 2016, 27, 975-984.	0.6	76
43	Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors. American Journal of Human Genetics, 2016, 98, 818-829.	2.6	34
44	Hypoxia-activated prodrugs: paths forward in the era of personalised medicine. British Journal of Cancer, 2016, 114, 1071-1077.	2.9	155
45	Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. JAMA Oncology, 2016, 2, 1598.	3.4	290
46	Progress in the mechanism and drug development of castration-resistant prostate cancer. Future Medicinal Chemistry, 2016, 8, 765-788.	1.1	7
47	Translation of Targeted Radiation Sensitizers into Clinical Trials. Seminars in Radiation Oncology, 2016, 26, 261-270.	1.0	16
48	Major milestones in translational oncology. BMC Medicine, 2016, 14, 110.	2.3	15
49	Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2016, 19, 398-405.	2.0	12
50	Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. EMBO Reports, 2016, 17, 1609-1623.	2.0	88
51	Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Research and Treatment, 2016, 160, 393-410.	1.1	58
52	Non-invasive actionable biomarkers for metastatic prostate cancer. Asian Journal of Urology, 2016, 3, 170-176.	0.5	8
53	Biomarkers for Metastatic Castration-resistant Prostate Cancer (mCRPC): Yes or No? Predictive and Response Biomarkers Towards Precision Medicine in mCRPC. European Urology Focus, 2016, 2, 465-466.	1.6	1
54	Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1113-1120.	1.5	5
55	Limits to Personalized Cancer Medicine. New England Journal of Medicine, 2016, 375, 1289-1294.	13.9	329
56	PARP inhibitors and stratified treatment of prostate cancer. Expert Review of Anticancer Therapy, 2016, 16, 1213-1215.	1.1	6

#	Article	IF	Citations
57	Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. Clinical Cancer Research, 2016, 22, 5651-5660.	3.2	116
58	NAD + Replenishment Improves Lifespan and Healthspan in Ataxia Telangiectasia Models via Mitophagy and DNA Repair. Cell Metabolism, 2016, 24, 566-581.	7.2	420
59	Clarifying the biological significance of the CHK 2 K373E somatic mutation discovered in The Cancer Genome Atlas database. FEBS Letters, 2016, 590, 4275-4286.	1.3	7
60	The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Medicine, 2016, 8, 79.	3.6	151
61	Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents â€“ A Potential Therapy for Cancer. Cancer Cell, 2016, 30, 637-650.	7.7	151
62	Re: Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. European Urology, 2016, 70, 703-704.	0.9	3
63	Targeting deficient DNA damage repair in gastric cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 1757-1766.	0.9	16
64	Utility of novel androgen receptor therapies in the real world: A nuanced approach. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 340-347.	0.8	2
65	Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. Annals of Oncology, 2016, 27, 2004-2016.	0.6	93
66	Raising the Bar for Therapeutic Trials in Advanced Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 2958-2960.	0.8	2
67	Biennial report on genitourinary cancers. European Journal of Cancer, 2016, 66, 125-130.	1.3	1
68	INT6/EIF3E Controls the RNF8-Dependent Ubiquitylation Pathway and Facilitates DNA Double-Strand Break Repair in Human Cells. Cancer Research, 2016, 76, 6054-6065.	0.4	7
69	Risk stratification of prostate cancer 2016. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, S54-S59.	0.6	6
70	Highlights in Genitourinary (Prostate) Cancer. JAMA Oncology, 2016, 2, 1257.	3.4	0
71	Precision medicine, genomics and drug discovery: Table 1.. Human Molecular Genetics, 2016, 25, R166-R172.	1.4	43
72	The oncologistsâ€™ unmet clinical needs for imaging in advanced prostate cancer. Clinical and Translational Imaging, 2016, 4, 423-431.	1.1	2
73	Transcript signatures that predict outcome and identify targetable pathways in MYCNâ€amplified neuroblastoma. Molecular Oncology, 2016, 10, 1461-1472.	2.1	14
74	Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1456-1463.	1.1	22

#	Article	IF	Citations
75	Familial prostate cancer. Seminars in Oncology, 2016, 43, 560-565.	0.8	49
76	Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective. Expert Review of Anticancer Therapy, 2016, 16, 1029-1037.	1.1	9
77	Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. Journal of Experimental and Clinical Cancer Research, 2016, 35, 179.	3.5	88
78	MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer. BMC Cancer, 2016, 16, 894.	1.1	31
79	Inherited HSD3B1 polymorphisms and hormonal therapy resistance. Lancet Oncology, The, 2016, 17, 1347-1349.	5.1	1
80	Synthetic lethality: the road to novel therapies for breast cancer. Endocrine-Related Cancer, 2016, 23, T39-T55.	1.6	17
81	DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities. Oncologist, 2016, 21, 940-945.	1.9	29
82	Liquid biopsy: ready to guide therapy in advanced prostate cancer?. BJU International, 2016, 118, 855-863.	1.3	61
83	Personalized treatment of prostate cancer: better knowledge of the patient, the disease and the medicine. Future Oncology, 2016, 12, 2359-2361.	1.1	4
84	Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer. Targeted Oncology, 2016, 11, 569-577.	1.7	15
85	Drug discovery in advanced prostate cancer: translating biology into therapy. Nature Reviews Drug Discovery, 2016, 15, 699-718.	21.5	111
86	An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy. Journal of Medicinal Chemistry, 2016, 59, 9575-9598.	2.9	166
87	Genetics of Pancreatic Cancer and Its Implications on Therapy. Surgical Clinics of North America, 2016, 96, 1207-1221.	0.5	12
88	Sequencing Treatment for Castration-Resistant Prostate Cancer. Current Treatment Options in Oncology, 2016, 17, 64.	1.3	29
89	DNA Repair Pathways as a Potential Target for Radiosensitization. , 2016, , 253-287.		0
90	Cell-free and circulating tumor cellâ€“based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 490-501.	0.8	11
91	NQO1 Bioactivatable Drugs Enhance Radiation Responses. , 2016, , 225-252.		1
92	Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Science Translational Medicine, 2016, 8, 362ps17.	5.8	518

#	Article	IF	Citations
93	Cytotoxic and targeted therapy for hereditary cancers. Hereditary Cancer in Clinical Practice, 2016, 14, 17.	0.6	37
94	PARP inhibitor combination therapy. Critical Reviews in Oncology/Hematology, 2016, 108, 73-85.	2.0	175
95	Advances in the management of castration resistant prostate cancer. BMJ, The, 2016, 355, i4405.	3.0	71
96	An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. BMC Cancer, 2016, 16, 621.	1.1	48
97	Circulating biomarkers to guide systemic therapy for urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 502-509.	0.8	8
98	There and Back Again: The Middle Earth of DNA Repair. Molecular Cancer Research, 2016, 14, 895-897.	1.5	1
99	Role of Biomarkers in the Development of PARP Inhibitors. Biomarkers in Cancer, 2016, 8s1, BIC.S36679.	3.6	57
100	Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. Clinical Medicine Insights: Oncology, 2016, 10s1, CMO.S34535.	0.6	34
102	The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment. Cancer Journal (Sudbury, Mass), 2016, 22, 357-361.	1.0	9
104	A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy. Cancer Research, 2016, 76, 4516-4524.	0.4	77
105	Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 469-476.	0.8	8
106	DNA Repair. Recent Results in Cancer Research, 2016, 198, 1-24.	1.8	13
107	Circulating Tumor Cell Count as an Indicator of Treatment Benefit in Advanced Prostate Cancer. European Urology, 2016, 70, 993-994.	0.9	4
108	Novel Use of Targeted Therapy via PARP-Inhibition in a Rare Form of Papillary Renal Cell Carcinoma: A Case Report and Literature Review. Clinical Genitourinary Cancer, 2016, 14, e445-e448.	0.9	5
109	Translational and clinical implications of the genetic landscape of prostate cancer. Nature Reviews Clinical Oncology, 2016, 13, 597-610.	12.5	63
110	Drugging DNA repair. Science, 2016, 352, 1178-1179.	6.0	71
111	When Genome Maintenance Goes Badly Awry. Molecular Cell, 2016, 62, 777-787.	4.5	64
112	New drugs in prostate cancer. Prostate International, 2016, 4, 37-42.	1.2	23

#	Article	IF	Citations
113	Evaluation of the methods to identify patients who may benefit from PARP inhibitor use. Endocrine-Related Cancer, 2016, 23, R267-R285.	1.6	28
114	Rare Genitourinary Tumors. , 2016, , .		0
115	PARP inhibition in castration-resistant prostate cancer. Future Oncology, 2016, 12, 577-580.	1.1	2
116	Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients. Journal of Endocrinological Investigation, 2016, 39, 729-738.	1.8	7
117	BRCAness revisited. Nature Reviews Cancer, 2016, 16, 110-120.	12.8	976
118	The Clinical Impact of BRCA2 Loss in Prostate Cancer. European Urology, 2016, 69, 996-997.	0.9	2
119	Multifaceted and personalized therapy of advanced prostate cancer. Current Opinion in Oncology, 2016, 28, 222-231.	1.1	5
120	Heat Shock Proteins Promote Cancer: It's a Protection Racket. Trends in Biochemical Sciences, 2016, 41, 311-323.	3.7	316
121	PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations. Annals of Oncology, 2016, 27, 755-757.	0.6	42
122	DNA repair targeted therapy: The past or future of cancer treatment?. , 2016, 160, 65-83.		307
123	Another surprising role for exosomes? Improving next-generation sequencing-based cancer diagnostics in liquid biopsies. Annals of Oncology, 2016, 27, 557-558.	0.6	6
124	DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?. Cancer Discovery, 2016, 6, 130-132.	7.7	44
125	Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer. Current Urology Reports, 2016, 17, 29.	1.0	22
126	Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nature Medicine, 2016, 22, 369-378.	15.2	572
127	Linking DNA Damage and Hormone Signaling Pathways in Cancer. Trends in Endocrinology and Metabolism, 2016, 27, 216-225.	3.1	52
128	DNA damage signalling barrier, oxidative stress and treatmentâ€relevant DNA repair factor alterations during progression of human prostate cancer. Molecular Oncology, 2016, 10, 879-894.	2.1	41
129	DNA Damage and Repair Pathway Profiles as Biomarkers in High-Risk Prostate Cancer. JAMA Oncology, 2016, 2, 480.	3.4	1
130	Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prevention Research, 2016, 9, 2-10.	0.7	130

#	Article	IF	Citations
131	Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, e233-e236.	0.9	15
132	Moving Beyond the Androgen Receptor in Advanced Prostate Cancer Commentary on: DNA-repair Defects and Olaparib in Metastatic Prostate Cancer. Urology, 2016, 89, 10-11.	0.5	2
133	Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. European Urology, 2016, 69, 992-995.	0.9	228
134	Molecular stratification and repair defects: revealing hidden treasures. Nature Reviews Urology, 2016, 13, 1-1.	1.9	3
135	Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer. Acta Clinica Belgica, 2017, 72, 6-11.	0.5	3
136	Synthetic lethality: emerging targets and opportunities in melanoma. Pigment Cell and Melanoma Research, 2017, 30, 183-193.	1.5	12
137	Prostate cancer, PI3K, PTEN and prognosis. Clinical Science, 2017, 131, 197-210.	1.8	146
138	Genomic hallmarks of localized, non-indolent prostate cancer. Nature, 2017, 541, 359-364.	13.7	462
139	Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nature Communications, 2017, 8, 13671.	5.8	182
140	Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2017, 16, 469-479.	1.9	41
141	Management of Prostate Cancer. , 2017, , .		5
142	Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 1086-1095.	0.8	383
143	The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer. Prostate Cancer and Prostatic Diseases, 2017, 20, 234-240.	2.0	4
144	Noncoding RNA for personalized prostate cancer treatment: utilizing the â€˜dark mattersâ€™ of the genome. Personalized Medicine, 2017, 14, 159-169.	0.8	0
145	Prostate Cancer Metastasis. , 2017, , 33-59.		2
146	Re: Inherited DNA-repair Gene Mutations in Men with Metastatic Prostate Cancer. European Urology, 2017, 71, 692.	0.9	1
147	Practical Polling for Prostate Cancer: AR-V7â€“based Treatment Selection. European Urology, 2017, 71, 883-885.	0.9	2
148	PARP-1 Expression Quantified by [¹⁸F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 9-15.	0.7	21

#	Article	IF	Citations
149	Comprehensive genomic profiling of malignant phyllodes tumors of the breast. Breast Cancer Research and Treatment, 2017, 162, 597-602.	1.1	38
150	Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase. DNA Repair, 2017, 52, 81-91.	1.3	63
151	Mechanisms of Therapeutic Resistance in Prostate Cancer. Current Oncology Reports, 2017, 19, 13.	1.8	103
152	Patient-derived xenografts as in vivo models for research in urological malignancies. Nature Reviews Urology, 2017, 14, 267-283.	1.9	65
153	Integrating phosphoproteomics into the clinical management of prostate cancer. Clinical and Translational Medicine, 2017, 6, 9.	1.7	6
154	Navigating the evolving therapeutic landscape in advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, S1-S13.	0.8	53
155	Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Offâ€Łabel Drug Use. Pharmacotherapy, 2017, 37, 1043-1051.	1.2	6
156	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discovery, 2017, 7, 620-629.	7.7	321
157	A comprehensive review of immunotherapies in prostate cancer. Critical Reviews in Oncology/Hematology, 2017, 113, 292-303.	2.0	55
158	Rapid and cost-effective high-throughput sequencing for identification of germline mutations of BRCA1 and BRCA2. Journal of Human Genetics, 2017, 62, 561-567.	1.1	17
159	Implementing Genome-Driven Oncology. Cell, 2017, 168, 584-599.	13.5	405
160	Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma. Scientific Reports, 2017, 7, 42980.	1.6	27
161	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repairâ€“deficient Prostate Cancer. European Urology, 2017, 72, 34-42.	0.9	179
162	Second-line chemotherapy for patients with advanced gastric cancer. Gastric Cancer, 2017, 20, 395-406.	2.7	31
163	ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib. Translational Oncology, 2017, 10, 190-196.	1.7	91
164	The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer. European Urology, 2017, 71, 748-749.	0.9	9
165	Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. Cancer Treatment Reviews, 2017, 54, 68-73.	3.4	64
166	PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Genes and Development, 2017, 31, 101-126.	2.7	524

#	Article	IF	Citations
167	The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. Leukemia and Lymphoma, 2017, 58, 2705-2716.	0.6	6
168	CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. Annals of Oncology, 2017, 28, 1495-1507.	0.6	91
169	Prostate Cancer and Immune Monitoring: Are We Heading Towards Better Selection of Patients and Treatment Strategies?. European Urology, 2017, 71, 788-789.	0.9	1
170	Cellular determinants and microenvironmental regulation of prostate cancer metastasis. Seminars in Cancer Biology, 2017, 44, 83-97.	4.3	54
171	Detection of copy number alterations in cell-free tumor DNA from plasma. BBA Clinical, 2017, 7, 120-126.	4.1	9
172	RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies. International Journal of Cancer, 2017, 141, 1286-1294.	2.3	80
173	Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treatment Reviews, 2017, 57, 16-27.	3.4	156
174	Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation. Molecular Cancer Therapeutics, 2017, 16, 1279-1289.	1.9	37
175	Application of Panel-Based Tests for Inherited Risk of Cancer. Annual Review of Genomics and Human Genetics, 2017, 18, 201-227.	2.5	26
176	Liquid biopsies and plasma DNA: paving the way for personalized medicine in metastatic castration-resistant prostate cancer. Annals of Oncology, 2017, 28, 1408-1409.	0.6	3
177	CHD1: a new treatment biomarker for recombination deficiency in castration resistant prostate cancer?. Annals of Oncology, 2017, 28, 1407-1408.	0.6	0
178	Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer. Journal of Physical Education and Sports Management, 2017, 3, a001362.	0.5	9
179	Acquiring evidence for precision prostate cancer care. Annals of Oncology, 2017, 28, 916-917.	0.6	1
180	ALDH1A3 correlates with luminal phenotype in prostate cancer. Tumor Biology, 2017, 39, 101042831770365.	0.8	12
181	The ETS family of oncogenic transcription factors in solid tumours. Nature Reviews Cancer, 2017, 17, 337-351.	12.8	234
182	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discovery, 2017, 7, 1006-1017.	7.7	341
183	Susceptibility of ATM-deficient pancreatic cancer cells to radiation. Cell Cycle, 2017, 16, 991-998.	1.3	24
184	A comprehensive map of molecular drug targets. Nature Reviews Drug Discovery, 2017, 16, 19-34.	21.5	1,608

#	Article	IF	Citations
185	Should we Perform Genetic Testing on Men with Metastatic Prostate Cancer?. Clinical Oncology, 2017, 29, e92.	0.6	1
186	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 75-87.	5.1	975
187	A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations. Current Opinion in Urology, 2017, 27, 475-480.	0.9	3
188	Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet. Targeted Oncology, 2017, 12, 401-412.	1.7	6
189	Commentary on â€œIntegrative clinical genomics of advanced prostate cancerâ€•. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 535.	0.8	307
190	Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer. Journal of Urology, 2017, 198, 265-266.	0.2	0
191	Commentary on â€œBiallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancerâ€•. Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Eur Urol. Jun 2016;69(6):992â€“5.. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 536.	0.8	7
192	High throughput single cell counting in droplet-based microfluidics. Scientific Reports, 2017, 7, 1366.	1.6	45
193	Drugging the Cancers Addicted to DNA Repair. Journal of the National Cancer Institute, 2017, 109, .	3.0	114
194	Commentary on â€œInherited DNA-repair gene mutations in men with metastatic prostate cancerâ€•. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robso. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 536-537.	0.8	0
195	Molecular biomarkers to guide precision medicine in localized prostate cancer. Expert Review of Molecular Diagnostics, 2017, 17, 791-804.	1.5	20
196	Radiotherapy for cranial and brain metastases from prostate cancer: a systematic review. Journal of Neuro-Oncology, 2017, 133, 531-538.	1.4	16
197	PARP Inhibitors in Prostate Cancer. Current Treatment Options in Oncology, 2017, 18, 37.	1.3	50
198	Targeting DNA damage response systems to impact cancer care. Current Problems in Cancer, 2017, 41, 247-250.	1.0	2
199	Treatment strategies for DNA repair-deficient prostate cancer. Expert Review of Clinical Pharmacology, 2017, 10, 889-898.	1.3	26
200	Precision oncology based on omics data: The NCT Heidelberg experience. International Journal of Cancer, 2017, 141, 877-886.	2.3	133
201	Androgen receptor inhibitorâ€“induced â€œBRCAnessâ€•and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Science Signaling, 2017, 10, .	1.6	200
202	PARP inhibitors as precision medicine for cancer treatment. National Science Review, 2017, 4, 576-592.	4.6	12

#	Article	IF	Citations
203	Adjunct Screening of NKX3.1 Expression Supports 5Î±-Reductase Inhibition Intervention in Prostate Cancer Active Surveillance. European Urology, 2017, 72, 507-508.	0.9	1
204	Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature. Current Medical Research and Opinion, 2017, 33, 1995-2008.	0.9	20
205	The association between germline <scp>BRCA2</scp> variants and sensitivity to platinumâ€based chemotherapy among men with metastatic prostate cancer. Cancer, 2017, 123, 3532-3539.	2.0	217
206	Exploiting <scp>DNA</scp> damage without repair: The activity of platinum chemotherapy in <scp>BRCA</scp>â€mutated prostate cancers. Cancer, 2017, 123, 3441-3444.	2.0	5
207	Emerging Variants of Castration-Resistant Prostate Cancer. Current Oncology Reports, 2017, 19, 32.	1.8	150
208	PARP Inhibitors for Cancer Therapy. Cell, 2017, 169, 183.	13.5	85
209	A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer. Value in Health, 2017, 20, 567-576.	0.1	54
210	The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. Cancer, 2017, 123, 1912-1924.	2.0	52
211	Re: Detection of Micrometastases by Flow Cytometry in Sentinel Lymph Nodes from Patients with Renal Tumours. European Urology, 2017, 71, 691-692.	0.9	1
212	Changing face of metastatic prostate cancer: the law of diminishing returns holds true. Current Opinion in Oncology, 2017, 29, 196-200.	1.1	4
213	Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma. Journal of Translational Medicine, 2017, 15, 61.	1.8	34
214	Resistance to Hormonal Therapy in Prostate Cancer. Handbook of Experimental Pharmacology, 2017, 249, 181-194.	0.9	7
215	Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clinical Cancer Research, 2017, 23, 4066-4076.	3.2	87
216	HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nature Medicine, 2017, 23, 517-525.	15.2	769
217	Genomic tests to guide prostate cancer management following diagnosis. Expert Review of Molecular Diagnostics, 2017, 17, 367-377.	1.5	11
218	BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. British Journal of Cancer, 2017, 116, 1021-1026.	2.9	61
219	PARP inhibitors: Synthetic lethality in the clinic. Science, 2017, 355, 1152-1158.	6.0	1,826
220	Biâ€allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. Journal of Pathology, 2017, 242, 165-177.	2.1	43

#	Article	IF	Citations
221	Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. Critical Reviews in Oncology/Hematology, 2017, 113, 171-190.	2.0	22
222	Germline DNA Repair Mutations and Response to Hormonal Therapy in Advanced Prostate Cancer. European Urology, 2017, 72, 43-44.	0.9	12
223	Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discovery, 2017, 7, 20-37.	7.7	488
224	Predictive value of epithelialâ€mesenchymalâ€transition (EMT) signature and PARPâ€1 in prostate cancer radioresistance. Prostate, 2017, 77, 1583-1591.	1.2	36
225	DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1063-1069.	2.3	21
226	Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform. Clinical Oncology, 2017, 29, 778-786.	0.6	13
227	Author Reply. Urology, 2017, 109, 17-18.	0.5	0
229	Editorial Comment. Urology, 2017, 109, 16-17.	0.5	0
230	Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. Nature Communications, 2017, 8, 857.	5.8	182
231	Computational Approaches to Identify Genetic Interactions for Cancer Therapeutics. Journal of Integrative Bioinformatics, 2017, 14, .	1.0	5
232	Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2017, 16, 2892-2901.	1.9	35
233	SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. Blood, 2017, 130, 2631-2641.	0.6	102
234	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Seminars in Oncology, 2017, 44, 187-197.	0.8	76
235	Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer. Lancet Oncology, The, 2017, 18, 1436-1437.	5.1	1
236	BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations. Expert Opinion on Investigational Drugs, 2017, 26, 1391-1397.	1.9	26
238	Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 676-677.	0.8	9
239	Approaches for Identifying Novel Targets in Precision Medicine: Lessons from DNA Repair. Advances in Experimental Medicine and Biology, 2017, 1007, 1-16.	0.8	3
240	Targeted Therapies and Immunotherapy in Prostate Cancer. , 2017, , 367-374.		0

#	Article	IF	Citations
241	Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions. Cancer Discovery, 2017, 7, 937-939.	7.7	33
242	Tissue-based biomarkers in prostate cancer. Expert Review of Precision Medicine and Drug Development, 2017, 2, 249-260.	0.4	20
243	A Novel Use of Olaparib for the Treatment of Metastatic Castrationâ€Recurrent Prostate Cancer. Pharmacotherapy, 2017, 37, 1406-1414.	1.2	21
244	Germline Mutations in DNA Repair Genes in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2017, 12, 1673-1678.	0.5	73
245	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clinical Cancer Research, 2017, 23, 7072-7083.	3.2	87
246	Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffeyâ€Holden Prostate Cancer Academy Meeting. Prostate, 2017, 77, 1478-1488.	1.2	7
247	Targeting androgen-independent pathways: new chances for patients with prostate cancer?. Critical Reviews in Oncology/Hematology, 2017, 118, 42-53.	2.0	25
248	Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nature Communications, 2017, 8, 374.	5.8	180
250	Germline versus somatic mutations in genetic atrial fibrillation. Heart Rhythm, 2017, 14, 1539-1540.	0.3	0
251	Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Therapeutic Advances in Medical Oncology, 2017, 9, 565-573.	1.4	58
252	Prostate Cancer Screening in a New Era of Genetics. Clinical Genitourinary Cancer, 2017, 15, 625-628.	0.9	24
253	<scp>BRCA</scp> 1 and <scp>BRCA</scp> 2 tumor suppressors protect against endogenous acetaldehyde toxicity. EMBO Molecular Medicine, 2017, 9, 1398-1414.	3.3	57
254	Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review. Expert Review of Anticancer Therapy, 2017, 17, 939-949.	1.1	6
255	Bioinformatoryâ€assisted analysis of nextâ€generation sequencing data for precision medicine in pancreatic cancer. Molecular Oncology, 2017, 11, 1413-1429.	2.1	20
256	The evolution of chemotherapy for the treatment of prostate cancer. Annals of Oncology, 2017, 28, 2658-2669.	0.6	57
257	Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors. Expert Opinion on Investigational Drugs, 2017, 26, 1063-1072.	1.9	8
258	Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. Clinical Cancer Research, 2017, 23, 6070-6077.	3.2	30
259	Nup153 and Nup50 promote recruitment of 53BP1 to DNA repair foci by antagonizing BRCA1-dependent events. Journal of Cell Science, 2017, 130, 3347-3359.	1.2	19

#	Article	IF	Citations
260	Integrative clinical genomics of metastatic cancer. Nature, 2017, 548, 297-303.	13.7	685
261	Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e1137-e1141.	0.9	8
264	New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. Endocrine Reviews, 2017, 38, 489-515.	8.9	241
265	Histopathological Evaluation in Prostate Cancer. , 2017, , 169-189.		0
266	Repression of BET activity sensitizes homologous recombinationâ€“proficient cancers to PARP inhibition. Science Translational Medicine, 2017, 9, .	5.8	180
267	Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clinical Cancer Research, 2017, 23, 6400-6410.	3.2	59
268	Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer. Urology, 2017, 109, 6-18.	0.5	15
269	Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis. Pharmacoeconomics, 2017, 35, 845-858.	1.7	10
271	Five Years of Multidisciplinary Care in Hereditary Cancer: Our Experience in a Spanish University Hospital. Oncology, 2017, 92, 68-74.	0.9	2
272	DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nature Communications, 2017, 8, 1751.	5.8	497
273	Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type. Gynecologic Oncology, 2017, 147, 626-633.	0.6	37
274	Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer. Trends in Molecular Medicine, 2017, 23, 1121-1137.	3.5	48
275	Combining immunotherapies for the treatment of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 694-700.	0.8	36
276	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nature Communications, 2017, 8, 1324.	5.8	584
277	Monogenic Diseases of DNA Repair. New England Journal of Medicine, 2017, 377, 1868-1876.	13.9	49
278	Synthetic lethality and cancer. Nature Reviews Genetics, 2017, 18, 613-623.	7.7	444
279	The Diagnosis and Treatment of Prostate Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 2532.	3.8	959
280	Use of Inosine Monophosphate Dehydrogenase Activity Assay to Determine the Specificity of PARP-1 Inhibitors. Methods in Molecular Biology, 2017, 1608, 337-342.	0.4	1

#	Article	IF	Citations
282	A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. Journal of Physical Education and Sports Management, 2017, 3, a001487.	0.5	25
283	The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nature Reviews Molecular Cell Biology, 2017, 18, 610-621.	16.1	1,041
284	Mutations in BRCA2 and taxane resistance in prostate cancer. Scientific Reports, 2017, 7, 4574.	1.6	32
285	Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients. Cancer Biology and Therapy, 2017, 18, 545-546.	1.5	2
286	Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient. Annals of Oncology, 2017, 28, 1158-1159.	0.6	3
287	Mechanisms of DNAâ€“protein crosslink repair. Nature Reviews Molecular Cell Biology, 2017, 18, 563-573.	16.1	208
288	PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. Molecular Cancer, 2017, 16, 86.	7.9	49
289	Germline genetic variants in men with prostate cancer and one or more additional cancers. Cancer, 2017, 123, 3925-3932.	2.0	45
290	Measurement of drug-target engagement in live cells by two-photon fluorescence anisotropy imaging. Nature Protocols, 2017, 12, 1472-1497.	5.5	19
291	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	288
292	Genomes of early onset prostate cancer. Current Opinion in Urology, 2017, 27, 481-487.	0.9	9
293	Immunotherapy of Prostate Cancer: Facts and Hopes. Clinical Cancer Research, 2017, 23, 6764-6770.	3.2	173
294	A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia. Molecular Cancer Therapeutics, 2017, 16, 2058-2068.	1.9	61
295	Relevance of DNA damage repair in the management of prostate cancer. Current Problems in Cancer, 2017, 41, 287-301.	1.0	16
296	New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer. Targeted Oncology, 2017, 12, 37-45.	1.7	10
297	Prostate cancer: Developing novel approaches to castrationâ€sensitive disease. Cancer, 2017, 123, 29-42.	2.0	8
298	Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radiumâ€223. Prostate, 2017, 77, 245-254.	1.2	6
299	Genetics meets pathology â€“ an increasingly important relationship. Journal of Pathology, 2017, 241, 119-122.	2.1	8

#	Article	IF	Citations
300	Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells. International Journal of Radiation Biology, 2017, 93, 194-203.	1.0	25
301	The molecular underpinnings of prostate cancer: impacts on management and pathology practice. Journal of Pathology, 2017, 241, 173-182.	2.1	36
302	NovelBRCA1andBRCA2Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas. Human Mutation, 2017, 38, 226-235.	1.1	55
303	Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Annals of Oncology, 2017, 28, 90-95.	0.6	24
304	Getting personal with prostate cancer: <scp>DNA</scp>â€repair defects and olaparib in metastatic prostate cancer. BJU International, 2017, 119, 8-9.	1.3	6
305	Proteomic profiling of human plasma for cancer biomarker discovery. Proteomics, 2017, 17, 1600240.	1.3	82
306	A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. Clinical Cancer Research, 2017, 23, 899-907.	3.2	37
307	The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. European Urology, 2017, 71, 237-246.	0.9	62
308	DNA Repair in Prostate Cancer: Biology and Clinical Implications. European Urology, 2017, 71, 417-425.	0.9	169
309	Expanding the Armamentarium for Castrate-resistant Prostate Cancer. European Urology, 2017, 71, 328-329.	0.9	1
310	The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. European Urology, 2017, 71, 680-687.	0.9	213
311	Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033. European Urology, 2017, 71, e56.	0.9	0
312	Exceptional Duration of Radium-223 in Prostate Cancer With a BRCA2 Mutation. Clinical Genitourinary Cancer, 2017, 15, e69-e71.	0.9	28
313	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffeyâ€"Holden Prostate Cancer Academy Meeting. Prostate, 2017, 77, 123-144.	1.2	6
314	PARP, transcription and chromatin modeling. Seminars in Cell and Developmental Biology, 2017, 63, 102-113.	2.3	55
315	PARP inhibition in BRCA2-mutated prostate cancer. Annals of Oncology, 2017, 28, 189-191.	0.6	12
316	Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer. European Urology, 2017, 71, 499.	0.9	26
317	Beyond Just Androgen Deprivation Therapy: Novel Therapies Combined With Radiation. Seminars in Radiation Oncology, 2017, 27, 87-93.	1.0	2

#	Article	IF	Citations
318	Tumor clone dynamics in lethal prostate cancer. European Urology, 2017, 71, 142-143.	0.9	2
319	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology, 2017, 283, 168-177.	3.6	81
321	Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer â€“ The urologists' perspective. Urological Science, 2017, 28, 190-196.	0.2	5
323	Heterogeneity of advanced prostate cancer: clinical implications of genomics. Trends in Urology & Men's Health, 2017, 8, 24-27.	0.2	0
324	Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation. JCO Precision Oncology, 2017, 1, 1-17.	1.5	27
325	Biallelic Deletion of PALB2 Occurs Across Multiple Tumor Types and Suggests Responsiveness to Poly (ADP-ribose) Polymerase Inhibition. JCO Precision Oncology, 2017, 1, 1-7.	1.5	3
326	Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision Making. JCO Precision Oncology, 2017, 1, 1-11.	1.5	5
327	Genetic Testing for Prostate Cancer in Clinical Practice. JCO Precision Oncology, 2017, 1, 1-3.	1.5	2
328	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 358-369.	1.8	9
329	Beyond the Androgen Receptor: Targeting Actionable Drivers of Prostate Cancer. JCO Precision Oncology, 2017, 1, 1-3.	1.5	4
331	Molecular Basis of PARP Inhibition and Future Opportunities in Ovarian Cancer Therapy. , 2017, , 129-150.		0
332	Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers, 2017, 9, 109.	1.7	36
333	Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer. Cancers, 2017, 9, 151.	1.7	54
334	Current status of poly(ADP-ribose) polymerase inhibitors and future directions. OncoTargets and Therapy, 2017, Volume 10, 5195-5208.	1.0	96
336	Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine. BioMed Research International, 2017, 2017, 1-9.	0.9	6
337	Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery. Oncotarget, 2017, 8, 18497-18512.	0.8	54
338	Emerging treatment options for ovarian cancer: focus on rucaparib . International Journal of Women's Health, 2017, Volume 9, 913-924.	1.1	19
339	Olaparib and somatic BRCA mutations. Oncotarget, 2017, 8, 43598-43599.	0.8	11

#	Article	IF	Citations
340	Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget, 2017, 8, 3724-3745.	0.8	95
341	Defective DNA repair mechanisms in prostate cancer: impact of olaparib. Drug Design, Development and Therapy, 2017, Volume11, 547-552.	2.0	26
342	Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer. International Journal of Molecular Sciences, 2017, 18, 1542.	1.8	25
343	Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget, 2017, 8, 28575-28587.	0.8	157
344	Patient-Derived Xenograft Models of Prostate Tumors. , 2017, , 217-228.		1
345	Germline Testing for Individuals With Pancreatic Cancer: The Benefits and Challenges to Casting a Wider Net. Journal of Clinical Oncology, 2017, 35, 3375-3377.	0.8	12
346	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology, 2017, 2017, 1-16.	1.5	286
347	Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2017, 1, 1-11.	1.5	13
348	A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. Oncotarget, 2017, 8, 83446-83456.	0.8	54
349	Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. Oncotarget, 2017, 8, 74049-74057.	0.8	14
350	Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget, 2017, 8, 69105-69124.	0.8	101
351	Next generation sequencing identifies â€˜interactomeâ€™ signatures in relapsed and refractory metastatic colorectal cancer. Journal of Gastrointestinal Oncology, 2017, 8, 20-31.	0.6	14
352	Molecular Tests for the Choice of Cancer Therapy. Current Pharmaceutical Design, 2017, 23, 4794-4806.	0.9	10
353	Clinical implications of PTEN loss in prostate cancer. Nature Reviews Urology, 2018, 15, 222-234.	1.9	408
355	Molecular Targeted Therapies of Prostate Cancer. Molecular Pathology Library, 2018, , 523-546.	0.1	1
356	Molecular Profiling of Pooled Circulating Tumor Cells from Prostate Cancer Patients Using a Dual-Antibody-Functionalized Microfluidic Device. Analytical Chemistry, 2018, 90, 3744-3751.	3.2	46
357	Inherited DNA-Repair Defects in Colorectal Cancer. American Journal of Human Genetics, 2018, 102, 401-414.	2.6	89
358	Olaparib is effective in combination with, and as maintenance therapy after, firstâ€line endocrine therapy in prostate cancer cells. Molecular Oncology, 2018, 12, 561-576.	2.1	21

#	Article	IF	Citations
359	Defining the Prognostic and Predictive Impact of Germline DNA Repair Mutations in Patients with Metastatic Castration-resistant Prostate Cancer. European Urology, 2018, 73, 694-695.	0.9	0
360	A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). Investigational New Drugs, 2018, 36, 451-457.	1.2	24
361	Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. Current Treatment Options in Oncology, 2018, 19, 16.	1.3	5
362	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. Journal of the National Cancer Institute, 2018, 110, 1030-1034.	3.0	90
363	Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 18.	0.4	6
364	Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer. Cell Reports, 2018, 22, 2236-2245.	2.9	60
365	Clinical and Genomic Characterization of Lowâ€“Prostate-specific Antigen, High-grade Prostate Cancer. European Urology, 2018, 74, 146-154.	0.9	72
366	Molecular diagnosis in breast cancer. Diagnostic Histopathology, 2018, 24, 71-82.	0.2	4
367	Î±-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studiesâ€”Part 2. Journal of Nuclear Medicine, 2018, 59, 1020-1027.	2.8	72
368	Precision Medicine and Progress in the Treatment of Hutchinson-Gilford Progeria Syndrome. JAMA - Journal of the American Medical Association, 2018, 319, 1663.	3.8	3
369	Re: Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. European Urology, 2018, 74, 397.	0.9	1
370	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics, 2018, 50, 682-692.	9.4	182
371	Genetic testing for hereditary prostate cancer: Current status and limitations. Cancer, 2018, 124, 3105-3117.	2.0	72
372	Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 2420-2427.	1.4	14
373	Delineation of the androgen-regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches. Current Opinion in Pharmacology, 2018, 41, 1-11.	1.7	11
374	Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. International Journal of Cancer, 2018, 143, 1236-1248.	2.3	37
375	Proteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells. Molecular and Cellular Proteomics, 2018, 17, 1170-1183.	2.5	13
376	Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. Journal of Physical Education and Sports Management, 2018, 4, a002279.	0.5	21

#	Article	IF	Citations
377	Poly ADPâ€ribose polymeraseâ€1 as a potential therapeutic target in Merkel cell carcinoma. Head and Neck, 2018, 40, 1676-1684.	0.9	9
378	Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy. , 2018, 188, 168-175.		40
379	Molecular and cellular mechanisms of castration resistant prostate cancer (Review). Oncology Letters, 2018, 15, 6063-6076.	0.8	116
380	Emerging Therapies in Metastatic Prostate Cancer. Current Oncology Reports, 2018, 20, 46.	1.8	22
381	PARP inhibitors and breast cancer: highlights and hang-ups. Expert Review of Precision Medicine and Drug Development, 2018, 3, 83-94.	0.4	4
382	High expression of NPRL2 is linked to poor prognosis in patients with prostate cancer. Human Pathology, 2018, 76, 141-148.	1.1	9
383	BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. Cell Reports, 2018, 22, 796-808.	2.9	103
384	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. European Urology, 2018, 73, 687-693.	0.9	99
385	Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. European Urology, 2018, 74, 218-225.	0.9	140
386	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discovery, 2018, 8, 444-457.	7.7	376
387	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathologica, 2018, 135, 601-615.	3.9	76
388	Rare germline mutations in African American men diagnosed with earlyâ€onset prostate cancer. Prostate, 2018, 78, 321-326.	1.2	20
389	Intraductal/ductal histology and lymphovascular invasion are associated with germline DNAâ€repair gene mutations in prostate cancer. Prostate, 2018, 78, 401-407.	1.2	105
390	Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wildâ€type BRCA pancreatic ductal adenocarcinoma. Cancer, 2018, 124, 1374-1382.	2.0	91
391	Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature Reviews Drug Discovery, 2018, 17, 167-181.	21.5	294
392	Metastatic Prostate Cancer. New England Journal of Medicine, 2018, 378, 645-657.	13.9	386
393	The potential of AR-V7 as a therapeutic target. Expert Opinion on Therapeutic Targets, 2018, 22, 201-216.	1.5	22
394	Clinical and Novel Biomarkers in the Management of Prostate Cancer. Current Treatment Options in Oncology, 2018, 19, 8.	1.3	16

#	Article	IF	Citations
395	When and how to use carboplatin in metastatic castration-resistant prostate cancer?. European Journal of Cancer, 2018, 92, 96-99.	1.3	2
396	IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. Clinical Cancer Research, 2018, 24, 1705-1715.	3.2	80
397	Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review. Future Oncology, 2018, 14, 431-442.	1.1	14
398	Current treatment strategies for advanced prostate cancer. International Journal of Urology, 2018, 25, 220-231.	0.5	164
399	TheÂmolecular biology of prostate cancer: current understanding and clinical implications. Prostate Cancer and Prostatic Diseases, 2018, 21, 22-36.	2.0	70
400	Targeting DNA repair: the genome as a potential biomarker. Journal of Pathology, 2018, 244, 586-597.	2.1	41
401	Immunotherapy for Prostate Cancer: An Evolving Landscape. , 2018, , 593-606.		2
402	Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 380-384.	0.8	13
403	Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit. Journal of Genetic Counseling, 2018, 27, 854-862.	0.9	5
404	The development of PARP as a successful target for cancer therapy. Expert Review of Anticancer Therapy, 2018, 18, 161-175.	1.1	16
405	Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer, 2018, 124, 1008-1015.	2.0	42
406	CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer. Expert Review of Molecular Diagnostics, 2018, 18, 155-163.	1.5	51
407	Molecular Biomarkers in the Clinical Management of Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030601.	2.9	11
408	Precision oncology in the age of integrative genomics. Nature Biotechnology, 2018, 36, 46-60.	9.4	104
409	Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer. Modern Pathology, 2018, 31, 143-155.	2.9	38
410	Clonal diversity revealed by morphoproteomic and copy number profiles of single prostate cancer cells at diagnosis. Convergent Science Physical Oncology, 2018, 4, 015003.	2.6	23
411	An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. Cancer Discovery, 2018, 8, 288-303.	7.7	107
412	Meeting report from the Prostate Cancer Foundation PSMAâ€directed radionuclide scientific working group. Prostate, 2018, 78, 775-789.	1.2	35

#	Article	IF	Citations
413	Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. BMC Cancer, 2018, 18, 354.	1.1	16
414	Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. Breast Cancer Research, 2018, 20, 28.	2.2	35
415	Male BRCA mutation carriers: clinical characteristics and cancer spectrum. BMC Cancer, 2018, 18, 179.	1.1	59
416	Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure. European Journal of Cancer, 2018, 96, 128-130.	1.3	9
417	Emerging Therapeutic Targets in Pancreatic Adenocarcinoma. , 2018, , 1613-1641.		2
418	Comment je prescris le Denosumab (XGEVA Â®). ProgrÃ¨s En Urologie - FMC, 2018, 28, F16-F17.	0.2	0
419	Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent. Molecular Cancer Research, 2018, 16, 1092-1102.	1.5	32
420	PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opinion on Emerging Drugs, 2018, 23, 123-133.	1.0	24
421	The resounding effect of DNA repair deficiency in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 385-388.	0.8	9
422	Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions. Current Opinion in Oncology, 2018, 30, 159-164.	1.1	3
423	Development and Application of Liquid Biopsies in Metastatic Prostate Cancer. Current Oncology Reports, 2018, 20, 35.	1.8	28
424	BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy. Cancer Letters, 2018, 423, 60-70.	3.2	31
425	Bromodomain-containing proteins in prostate cancer. Molecular and Cellular Endocrinology, 2018, 462, 31-40.	1.6	25
426	A multiâ€centre phase I trial of the <scp>PARP</scp> inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, Tâ€prolymphocytic leukaemia or mantle cell lymphoma. British Journal of Haematology, 2018, 182, 429-433.	1.2	23
427	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	0.9	488
428	CCDC6: the identity of a protein known to be partner in fusion. International Journal of Cancer, 2018, 142, 1300-1308.	2.3	26
429	Prognostic parameter for high risk prostate cancer patients at initial presentation. Prostate, 2018, 78, 11-16.	1.2	24
430	Mechanisms of DNA damage repair in adult stem cells and implications for cancer formation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 89-101.	1.8	40

#	Article	IF	Citations
431	Preclinical and Coclinical Studies in Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030544.	2.9	3
432	Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 209-216.	3.2	47
433	Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nature Reviews Clinical Oncology, 2018, 15, 168-182.	12.5	7
434	Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis. Oncogene, 2018, 37, 313-322.	2.6	83
435	EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Oncogene, 2018, 37, 208-217.	2.6	79
436	Clinical utility of emerging liquid biomarkers in advanced prostate cancer. Cancer Genetics, 2018, 228-229, 151-158.	0.2	11
437	Prostate cancer immunotherapy. Current Opinion in Urology, 2018, 28, 15-24.	0.9	40
438	Prostate Cancer Germline Variations and Implications for Screening and Treatment. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030379.	2.9	25
439	Treatment of Advanced Prostate Cancerâ€”A Review of Current Therapies and Future Promise. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030635.	2.9	128
440	Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations. Pathology, 2018, 50, 60-73.	0.3	29
441	Platinum sensitivity in metastatic prostate cancer: does histology matter?. Prostate Cancer and Prostatic Diseases, 2018, 21, 92-99.	2.0	17
442	Promising immunotherapy for prostate cancer. Expert Opinion on Biological Therapy, 2018, 18, 109-120.	1.4	5
443	Germline BRCA mutation in male carriersâ€”ripe for precision oncology?. Prostate Cancer and Prostatic Diseases, 2018, 21, 48-56.	2.0	13
444	PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene, 2018, 37, 341-351.	2.6	98
445	Oxaliplatinâ€induced enteric neuronal loss and intestinal dysfunction is prevented by coâ€treatment with BGPâ€15. British Journal of Pharmacology, 2018, 175, 656-677.	2.7	34
446	DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223. Clinical Genitourinary Cancer, 2018, 16, 106-110.	0.9	12
447	Targeting the MYCNâ€“PARPâ€“DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2018, 24, 696-707.	3.2	80
448	SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). Clinical and Translational Oncology, 2018, 20, 57-68.	1.2	17

#	Article	IF	Citations
449	Genomic Markers in Prostate Cancer Decision Making. European Urology, 2018, 73, 572-582.	0.9	201
450	Prevalence of Homologous Recombinationâ€“Related Gene Mutations Across Multiple Cancer Types. JCO Precision Oncology, 2018, 2018, 1-13.	1.5	215
451	Applying Precision Oncology Principles in Radiation Oncology. JCO Precision Oncology, 2018, 2, 1-23.	1.5	12
452	Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data. JCO Precision Oncology, 2018, 2018, 1-15.	1.5	16
453	Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. Journal of Clinical Oncology, 2018, 36, 2863-2871.	0.8	158
454	Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 372-381.	1.8	25
455	BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy. JCO Precision Oncology, 2018, 2, 1-10.	1.5	4
456	Polyclonal BRCA2 Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer. JCO Precision Oncology, 2018, 2, 1-5.	1.5	16
457	Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations. JCO Precision Oncology, 2018, 2, 1-8.	1.5	32
458	Recent trends in the management of advanced prostate cancer. F1000Research, 2018, 7, 1513.	0.8	69
459	Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precision Oncology, 2018, 2018, 1-14.	1.5	14
460	Targeting DNA Repair in Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 1017-1019.	0.8	4
461	Clinical Activity of Olaparib in Urothelial Bladder Cancer With DNA Damage Response Gene Mutations. JCO Precision Oncology, 2018, 2, 1-7.	1.5	15
462	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology, 2018, 36, 414-424.	0.8	155
463	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. Journal of Clinical Oncology, 2018, 36, 991-999.	0.8	169
464	The Winds of Change: Emerging Therapeutics in Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 382-390.	1.8	2
465	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2386-2394.	0.8	276
466	Men with a susceptibility to prostate cancer and the role of genetic based screening. Translational Andrology and Urology, 2018, 7, 61-69.	0.6	19

#	Article	IF	Citations
467	Mechanisms of Drug Resistance in Cancer Therapy. Handbook of Experimental Pharmacology, 2018, , .	0.9	1
468	Metastatic Prostate Cancer in a RAD51C Mutation Carrier. Clinical Medicine and Research, 2018, 16, 69-72.	0.4	3
469	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget, 2018, 9, 28561-28571.	0.8	129
470	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. Journal of Clinical Investigation, 2018, 128, 4441-4453.	3.9	155
471	Homologous Recombination Deficiency in Patients With Pancreatic Ductal Adenocarcinoma and Response to Chemotherapy. JCO Precision Oncology, 2018, 2, 1-11.	1.5	13
472	Reflex Testing for Germline BRCA1, BRCA2, PALB2, and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries. JCO Precision Oncology, 2018, 2, 1-16.	1.5	18
473	Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer. JCO Precision Oncology, 2018, 2, 1-8.	1.5	2
474	Case of Basal Cell Carcinoma of the Prostate Successfully Treated Before and After a BRCA2 Reversion Mutation. JCO Precision Oncology, 2018, 2, 1-5.	1.5	3
476	Poly (ADP-Ribose) Polymerase (PARP), an Emerging Target for Controlling Metastatic Prostate Cancer under BRCAness. Journal of Oncology Translational Research, 2018, 04, .	0.2	0
477	Das metastasierte Prostatakarzinom - trotz aller Fortschritte eine Herausforderung. Karger Kompass Onkologie, 2018, 5, 146-147.	0.0	0
478	Genetic Susceptibility. Molecular Pathology Library, 2018, , 57-78.	0.1	0
479	Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Medicine, 2018, 10, 85.	3.6	94
480	Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer. Asian Journal of Andrology, 2018, 20, 230.	0.8	9
481	High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer. Scientific Reports, 2018, 8, 17239.	1.6	29
482	PARPâ€1 regulates DNA repair factor availability. EMBO Molecular Medicine, 2018, 10, .	3.3	52
483	PARPs in genome stability and signal transduction: implications for cancer therapy. Biochemical Society Transactions, 2018, 46, 1681-1695.	1.6	56
484	Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer. Expert Opinion on Emerging Drugs, 2018, 23, 271-282.	1.0	15
485	Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. OncoTargets and Therapy, 2018, Volume 11, 7353-7368.	1.0	58

#	Article	IF	Citations
486	Therapeutic Targets for Adrenocortical Carcinoma in the Genomics Era. Journal of the Endocrine Society, 2018, 2, 1259-1274.	0.1	38
487	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. , 2018, 6, 141.		214
488	Development of PARP and Immune-Checkpoint Inhibitor Combinations. Cancer Research, 2018, 78, 6717-6725.	0.4	155
489	Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors. Current Pharmacogenomics and Personalized Medicine, 2018, 16, 108-117.	0.2	0
490	Advanced prostate cancer update 2018. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 9-12.	0.7	6
491	PARP inhibitor reâ€˜sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis. Molecular Medicine Reports, 2018, 19, 75-84.	1.1	7
492	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. Frontiers in Oncology, 2018, 8, 397.	1.3	20
493	A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. Molecular Cancer Therapeutics, 2018, 17, 2702-2709.	1.9	30
494	Germline Genetic Testing in Prostate Cancer â€“ Further Enrichment in Variant Histologies?. Oncoscience, 2018, 5, 62-64.	0.9	7
495	Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?. Frontiers in Cell and Developmental Biology, 2018, 6, 71.	1.8	9
496	A <scp>RAD</scp> 51 assay feasible in routine tumor samples calls <scp>PARP</scp> inhibitor response beyond <scp>BRCA</scp> mutation. EMBO Molecular Medicine, 2018, 10, .	3.3	169
498	Genomic analysis of DNA repair genes and androgen signaling in prostate cancer. BMC Cancer, 2018, 18, 960.	1.1	55
499	Advancing therapies in metastatic castration-resistant prostate cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 1797-1804.	0.9	23
500	Treater to Target: A Urologistâ€™s Personal Experience with Prostate Cancer. , 2018, , 149-159.		0
502	Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment. Advances in Experimental Medicine and Biology, 2018, 1096, 117-133.	0.8	58
503	Mutational interactions define novel cancer subgroups. Nature Communications, 2018, 9, 4353.	5.8	26
504	Genitourinary Pathology Reporting Parameters Most Relevant to the Medical Oncologist. Surgical Pathology Clinics, 2018, 11, 877-891.	0.7	0
505	Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II. Nature Communications, 2018, 9, 4394.	5.8	27

#	Article	IF	Citations
506	Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report. BMC Medical Genetics, 2018, 19, 185.	2.1	8
507	A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer and Metastasis Reviews, 2018, 37, 599-614.	2.7	63
508	Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. Cancer Treatment Reviews, 2018, 70, 168-177.	3.4	55
509	RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancerâ€"From Cell Line Models to Liquid Biopsies. Diagnostics, 2018, 8, 60.	1.3	15
510	Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treatment Reviews, 2018, 71, 1-7.	3.4	91
511	ASCO 2018: highlights of urothelial cancer and prostate cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 284-290.	0.3	7
512	Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma. Clinical Sarcoma Research, 2018, 8, .	2.3	3
513	Genome-Based Classification and Therapy of Prostate Cancer. Diagnostics, 2018, 8, 62.	1.3	16
514	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. Lancet Oncology, The, 2018, 19, 1360-1371.	5.1	61
515	Genetics and biology of prostate cancer. Genes and Development, 2018, 32, 1105-1140.	2.7	434
516	Can Early Clinical Trials Help Deliver More Precise Cancer Care?. , 2018, , 115-128.		0
517	The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells. Cell Reports, 2018, 23, 2107-2118.	2.9	110
518	BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy. Clinical Nuclear Medicine, 2018, 43, 609-610.	0.7	9
519	MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer. Scientific Reports, 2018, 8, 7820.	1.6	33
520	Biomarkers for Homologous Recombination Deficiency in Cancer. Journal of the National Cancer Institute, 2018, 110, 704-713.	3.0	223
521	Molecular Subtypes of Prostate Cancer. Current Oncology Reports, 2018, 20, 58.	1.8	77
522	Therapeutic strategies for upper tract urothelial carcinoma. Expert Review of Anticancer Therapy, 2018, 18, 765-774.	1.1	18
525	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 280-284.	1.0	33

#	Article	IF	Citations
526	Sensitization of prostate cancer to radiation therapy: Molecules and pathways to target. Radiotherapy and Oncology, 2018, 128, 283-300.	0.3	12
527	Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer. Bladder Cancer, 2018, 4, 9-18.	0.2	18
528	Castration-resistance prostate cancer: what is in the pipeline?. Minerva Urology and Nephrology, 2018, 70, 22-41.	1.3	17
529	When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age. Annals of Internal Medicine, 2018, 169, 233.	2.0	20
530	Interference with DNA repair after ionizing radiation by a pyrrole-imidazole polyamide. PLoS ONE, 2018, 13, e0196803.	1.1	4
531	Small Molecules in Oncology. Recent Results in Cancer Research, 2018, , .	1.8	5
532	Modified Citrus Pectin as a Potential Sensitizer for Radiotherapy in Prostate Cancer. Integrative Cancer Therapies, 2018, 17, 1225-1234.	0.8	33
533	Olaparib. Recent Results in Cancer Research, 2018, 211, 217-233.	1.8	60
534	SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. Clinical Cancer Research, 2018, 24, 5585-5593.	3.2	113
535	Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer. Frontiers in Oncology, 2018, 8, 28.	1.3	18
536	Precision medicine applications in prostate cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877692.	1.4	12
537	PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials. Current Drug Targets, 2018, 19, 21-37.	1.0	100
538	Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities. International Journal of Molecular Sciences, 2018, 19, 1255.	1.8	50
539	Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. Clinical Cancer Research, 2018, 24, 5458-5470.	3.2	43
540	PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells. Journal of Experimental and Clinical Cancer Research, 2018, 37, 153.	3.5	73
541	Recent Advances in Prostate Cancer Treatment and Drug Discovery. International Journal of Molecular Sciences, 2018, 19, 1359.	1.8	183
542	Clinical Trials in CRPC. , 2018, , 189-195.		0
543	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	13.5	459

#	Article	IF	Citations
544	Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878665.	1.4	105
545	Castration-Resistant Prostate Cancer: Sequencing Oral and Infusion Agents. Current Urology Reports, 2018, 19, 73.	1.0	3
546	Science in Focus: Biological Optimisation of Radiotherapy Fraction Size in an Era of Immune Oncology. Clinical Oncology, 2018, 30, 605-608.	0.6	6
547	Novel Approaches of Treatment with Radium-223 Targeted Therapy. , 2018, , 379-391.		0
548	Identification of fluorescence in situ hybridization assay markers for prediction of disease progression in prostate cancer patients on active surveillance. BMC Cancer, 2018, 18, 2.	1.1	6
549	Modulation of hypersensitivity to oxidative DNA damage in ATM defective cells induced by potassium bromate by inhibition of the Poly (ADP-ribose) polymerase (PARP). Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2018, 836, 117-123.	0.9	3
550	A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clinical Cancer Research, 2018, 24, 4332-4345.	3.2	154
551	Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer. Drug Design, Development and Therapy, 2018, Volume 12, 605-617.	2.0	26
552	68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer. Radiologia Medica, 2018, 123, 952-965.	4.7	16
553	Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer â€“ recent developments and future directions. Expert Opinion on Investigational Drugs, 2018, 27, 811-822.	1.9	5
554	The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Nature Communications, 2018, 9, 3292.	5.8	153
555	BRCA1 Interacting Protein COBRA1 Facilitates Adaptation to Castrate-Resistant Growth Conditions. International Journal of Molecular Sciences, 2018, 19, 2104.	1.8	6
556	Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation. Expert Review of Anticancer Therapy, 2018, 18, 947-958.	1.1	5
557	Prostate cancer in the era of â€œOmicâ€•medicine: recognizing the importance of DNA damage repair pathways. Annals of Translational Medicine, 2018, 6, 161-161.	0.7	7
558	Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer. Nuclear Medicine and Biology, 2018, 66, 26-31.	0.3	29
559	Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer. Current Opinion in Supportive and Palliative Care, 2018, 12, 339-343.	0.5	9
560	A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology, 2018, 29, 1895-1902.	0.6	424
561	BRCAness and prostate cancer: diagnostic and therapeutic considerations. Prostate Cancer and Prostatic Diseases, 2018, 21, 488-498.	2.0	12

#	Article	IF	Citations
562	SPOP promotes transcriptional expression of DNA repair and replication factors to prevent replication stress and genomic instability. Nucleic Acids Research, 2018, 46, 9484-9495.	6.5	39
563	Alternative splicing in prostate cancer. Nature Reviews Clinical Oncology, 2018, 15, 663-675.	12.5	142
564	Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, The, 2018, 19, 975-986.	5.1	296
565	Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?. Lancet Oncology, The, 2018, 19, 860-861.	5.1	7
566	Liquid biopsy approach in the management of prostate cancer. Translational Research, 2018, 201, 60-70.	2.2	12
567	BRCA1/2 testing: therapeutic implications for breast cancer management. British Journal of Cancer, 2018, 119, 141-152.	2.9	142
568	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell, 2018, 173, 1770-1782.e14.	13.5	400
569	Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. European Urology Oncology, 2018, 1, 151-159.	2.6	28
570	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	9.4	652
571	Radiation biology and oncology in the genomic era. British Journal of Radiology, 2018, 91, 20170949.	1.0	25
572	Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell, 2018, 174, 433-447.e19.	13.5	258
573	PARP Inhibition to Enhance Response to Chemotherapy. , 2019, , 231-257.		1
574	Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy. European Urology Focus, 2019, 5, 416-424.	1.6	20
576	Implementing precision cancer medicine in the genomic era. Seminars in Cancer Biology, 2019, 55, 16-27.	4.3	24
577	Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genetics in Medicine, 2019, 21, 213-223.	1.1	151
578	Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer and Prostatic Diseases, 2019, 22, 24-38.	2.0	215
579	Sequencing strategies in the new treatment landscape of prostate cancer. Future Oncology, 2019, 15, 2967-2982.	1.1	6
580	Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers. Expert Opinion on Therapeutic Targets, 2019, 23, 773-785.	1.5	22

#	Article	IF	Citations
581	Screening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer. Frontiers in Oncology, 2019, 9, 661.	1.3	11
582	Pathological Assessment of Prostate Cancer. , 2019, , 159-177.		0
583	Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer. Cells, 2019, 8, 860.	1.8	34
584	Defining End Points in Phase II Trials of Metastatic Castration-Resistant Prostate Cancer. Re: Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. Clinical Genitourinary Cancer, 2019, 17, e886-e887.	0.9	1
585	Re: Daniel A. Leongamornlert, Edward J. Saunders, Sarah Wakerell, et al., Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. Eur Urol 2019;76:329â€“37. European Urology, 2019, 76, e128-e129.	0.9	1
586	Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. Medicines (Basel, Switzerland), 2019, 6, 82.	0.7	68
587	Leveraging Clinical Tumor-Profiling Programs to Achieve Comprehensive Germline-Inclusive Precision Cancer Medicine. JCO Precision Oncology, 2019, 3, 1-3.	1.5	6
588	Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data. Journal of Medical Economics, 2019, 22, 1080-1087.	1.0	4
589	Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e923-e929.	0.9	9
590	Biomarkers for platinum sensitivity in bladder cancer: are we there yet?. Translational Andrology and Urology, 2019, 8, S236-S239.	0.6	4
592	Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 813.e1-813.e9.	0.8	16
594	Molecular Underpinnings Governing Genetic Complexity of ETS-Fusion-Negative Prostate Cancer. Trends in Molecular Medicine, 2019, 25, 1024-1038.	3.5	10
595	Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. European Urology, 2019, 76, 469-478.	0.9	269
596	PARP Inhibitors in Prostate Cancerâ€"The Preclinical
Rationale and Current Clinical Development. Genes, 2019, 10, 565.	1.0	46
597	Current status of liquid biopsies for the detection and management of prostate cancer . Cancer Management and Research, 2019, Volume 11, 5271-5291.	0.9	47
598	Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors. International Journal of Molecular Sciences, 2019, 20, 3100.	1.8	32
599	Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 541-552.	1.5	14
600	Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 14573-14582.	3.3	69

#	Article	IF	Citations
601	Durvalumab in cancer medicine: a comprehensive review. Expert Opinion on Biological Therapy, 2019, 19, 927-935.	1.4	36
602	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. Radiology, 2019, 292, 273-286.	3.6	46
603	Personalised treatment for prostate cancer patients: are we there yet?. AME Medical Journal, 2019, 4, 2-2.	0.4	1
604	Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2019, 84, 1289-1301.	1.1	29
605	Assessment of Diagnostic Outcomes of RNA Genetic Testing for Hereditary Cancer. JAMA Network Open, 2019, 2, e1913900.	2.8	54
606	RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies. Cancers, 2019, 11, 1561.	1.7	35
607	Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncology, The, 2019, 20, 1740-1749.	5.1	147
608	PARP Inhibition in Cancer: An Update on Clinical Development. Targeted Oncology, 2019, 14, 657-679.	1.7	133
609	Olaparib Quantification in Human Plasma for Clinical Purposes using High-Performance Liquid Chromatography with UV detector. Analytical Chemistry Letters, 2019, 9, 526-534.	0.4	3
610	ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. Molecular Cancer Therapeutics, 2019, 18, 1899-1908.	1.9	52
611	Plasma Androgen Receptor in Prostate Cancer. Cancers, 2019, 11, 1719.	1.7	13
612	Hereditary prostate cancer â€“ Primetime for genetic testing?. Cancer Treatment Reviews, 2019, 81, 101927.	3.4	20
613	Radium-223 mechanism of action: implications for use in treatment combinations. Nature Reviews Urology, 2019, 16, 745-756.	1.9	71
614	Germline mutation in DNA â€•repair genes is associated with poor survival in BRCA 1/2â€•negative breast cancer patients. Cancer Science, 2019, 110, 3368-3374.	1.7	6
615	A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation. Pathology International, 2019, 69, 715-720.	0.6	14
616	Metronomic Oral Cyclophosphamide in 2 HeavilyÂPretreated Patients With Metastatic Castration-resistant Prostate Cancer With Homologous Recombination Deficiency (HRD): A Case Report. Clinical Genitourinary Cancer, 2019, 17, 157-160.	0.9	3
617	Emerging therapeutic agents for genitourinary cancers. Journal of Hematology and Oncology, 2019, 12, 89.	6.9	33
618	Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells. Breast Cancer Research, 2019, 21, 104.	2.2	45

#	Article	IF	Citations
619	Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2019, 9, 858.	1.3	125
620	Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. Journal of Clinical Oncology, 2019, 37, 2961-2967.	0.8	13
621	Time is running out for sand. Nature, 2019, 571, 29-31.	13.7	260
622	New name for breast-cancer syndrome could help to save lives. Nature, 2019, 571, 27-29.	13.7	16
623	Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review. Future Oncology, 2019, 15, 3283-3303.	1.1	18
624	A Nucleolar PARtnership Expands PARP Roles in RNA Biology and the Clinical Potential of PARP Inhibitors. Molecular Cell, 2019, 75, 1089-1091.	4.5	6
625	Future therapeutic strategies for metastatic prostate cancer. Tijdschrift Voor Urologie, 2019, 9, 117-130.	0.1	5
626	Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.. Cancers, 2019, 11, 1355.	1.7	54
627	Morpho-Molecular Assessment Indicates New Prognostic Aspects and Personalized Therapeutic Options in Sinonasal Melanoma. Cancers, 2019, 11, 1329.	1.7	9
628	The BRCA2 mutation status shapes the immune phenotype of prostate cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1621-1633.	2.0	38
629	Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. Frontiers in Oncology, 2019, 9, 801.	1.3	205
630	Positron-Emission Tomographic Imaging of a Fluorine 18â€“Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patientâ€“Derived Xenografts. Journal of Thoracic Oncology, 2019, 14, 1743-1752.	0.5	14
631	Towards precision oncology in advanced prostate cancer. Nature Reviews Urology, 2019, 16, 645-654.	1.9	156
632	Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. BMC Cancer, 2019, 19, 901.	1.1	33
633	Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: study protocol. BMC Pediatrics, 2019, 19, 31.	0.7	9
634	Whole genome sequencing of breast cancer. Apmis, 2019, 127, 303-315.	0.9	23
635	Treatment of Advanced Prostate Cancer. Annual Review of Medicine, 2019, 70, 479-499.	5.0	417
636	The lysineâ€specific methyltransferase <scp>KMT</scp> 2C/ <scp>MLL</scp> 3 regulates <scp>DNA</scp> repair components in cancer. EMBO Reports, 2019, 20, .	2.0	93

#	Article	IF	Citations
637	Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas. International Journal of Cancer, 2019, 145, 1209-1220.	2.3	23
638	PET Imaging of PARP Expression Using 18F-Olaparib. Journal of Nuclear Medicine, 2019, 60, 502-503.	2.8	2
639	Epigenetic Control of Gene Expression in the Normal and Malignant Human Prostate: A Rapid Response Which Promotes Therapeutic Resistance. International Journal of Molecular Sciences, 2019, 20, 2437.	1.8	7
640	Chlorambucil targets <scp>BRCA</scp> 1/2â€deficient tumours and counteracts <scp>PARP</scp> inhibitor resistance. EMBO Molecular Medicine, 2019, 11, e9982.	3.3	26
641	Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-9.	1.5	26
642	Cancer Genomics for Oncologists: Cancer Risk and Management of BRCA1 and BRCA2 Carriers. Current Genetic Medicine Reports, 2019, 7, 116-123.	1.9	0
643	Evolution of the Liquid Biopsy in Metastatic Prostate Cancer. Urology, 2019, 132, 1-9.	0.5	13
644	The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers. Cancer Treatment and Research, 2019, 178, 81-108.	0.2	2
645	DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies. DNA Repair, 2019, 80, 59-84.	1.3	30
646	A decade of clinical development of PARP inhibitors in perspective. Annals of Oncology, 2019, 30, 1437-1447.	0.6	437
647	Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?. ESMO Open, 2019, 4, e000480.	2.0	47
648	High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer. Npj Genomic Medicine, 2019, 4, 13.	1.7	63
649	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clinical Genitourinary Cancer, 2019, 17, 275-282.e1.	0.9	42
650	Prostate Cancer Incidence and Mortality in Relationship to Family History of Prostate Cancer; Findings From The PLCO Trial. Clinical Genitourinary Cancer, 2019, 17, e837-e844.	0.9	14
651	Hereditary Cancer Syndromesâ€"A Primer on Diagnosis and Management. Mayo Clinic Proceedings, 2019, 94, 1084-1098.	1.4	39
652	Adrenocortical carcinoma â€" towards genomics guided clinical care. Nature Reviews Endocrinology, 2019, 15, 548-560.	4.3	92
653	Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations. BMC Cancer, 2019, 19, 535.	1.1	77
654	Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. European Journal of Cancer, 2019, 116, 116-136.	1.3	134

#	Article	IF	Citations
655	Identification of critical pathways and hub genes in TP53 mutation prostate cancer by bioinformatics analysis. Biomarkers in Medicine, 2019, 13, 831-840.	0.6	8
656	Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer. BMC Urology, 2019, 19, 33.	0.6	8
657	The DNA Damaging Revolution: PARP Inhibitors and Beyond. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 185-195.	1.8	144
658	The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 79-86.	1.8	73
659	Contribution of Epithelial Plasticity to Therapy Resistance. Journal of Clinical Medicine, 2019, 8, 676.	1.0	42
660	Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials . Cancer Management and Research, 2019, Volume 11, 3061-3078.	0.9	10
661	Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Translational Oncology, 2019, 12, 871-878.	1.7	22
662	Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer. JCO Precision Oncology, 2019, 3, 1-12.	1.5	20
663	Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11428-11436.	3.3	839
664	Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452â€“8. European Urology, 2019, 76, e109-e110.	0.9	4
666	The PHLPP2 phosphatase is a druggable driver of prostate cancer progression. Journal of Cell Biology, 2019, 218, 1943-1957.	2.3	33
669	Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. JCO Precision Oncology, 2019, 3, 1-23.	1.5	63
670	Epithelial ovarian cancer: Evolution of management in the era of precision medicine. Ca-A Cancer Journal for Clinicians, 2019, 69, 280-304.	157.7	821
671	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	2.3	76
672	Outcomes of universal germline testing for men with prostate cancer in an Australian tertiary center. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 257-261.	0.7	5
674	Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. Journal of Clinical Oncology, 2019, 37, 2257-2269.	0.8	135
675	Functional classification of ATM variants in ataxiaâ€telangiectasia patients. Human Mutation, 2019, 40, 1713-1730.	1.1	27
676	Nuclear Receptors. Methods in Molecular Biology, 2019, , .	0.4	1

#	Article	IF	Citations
677	Detection of ADP-Ribosylation of the Androgen Receptor Using the Recombinant Macrodomain AF1521 from Archaeoglobus fulgidus. Methods in Molecular Biology, 2019, 1966, 107-124.	0.4	9
678	The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A metaâ€anâ€analysis. Prostate, 2019, 79, 880-895.	1.2	100
680	Non-NAD-like PARP-1 inhibitors in prostate cancer treatment. Biochemical Pharmacology, 2019, 167, 149-162.	2.0	21
681	Metastatic Prostate Cancer: Effects of Genetic Testing on Care. , 2019, 23, 32-35.		0
682	Relevance of radium-223 in hospital clinical practice from a medical oncologist point of view. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2019, 38, 106-111.	0.1	0
683	Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance. Journal of Physical Education and Sports Management, 2019, 5, a003657.	0.5	36
684	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. Scientific Reports, 2019, 9, 2858.	1.6	38
686	Somatic alterations detected in diagnostic prostate biopsies provide an inadequate representation of multifocal prostate cancer. Prostate, 2019, 79, 920-928.	1.2	9
687	Emerging therapeutic targets for patients with advanced prostate cancer. Cancer Treatment Reviews, 2019, 76, 1-9.	3.4	26
688	A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 14-22.	1.2	8
689	The Tumor Immune Contexture of Prostate Cancer. Frontiers in Immunology, 2019, 10, 603.	2.2	143
690	Lymph node metastasis in oral cancer is strongly associated with chromosomal instability and DNA repair defects. International Journal of Cancer, 2019, 145, 2568-2579.	2.3	33
691	Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. Current Oncology Reports, 2019, 21, 42.	1.8	15
692	A Case of Antiâ€“PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema. Clinical Genitourinary Cancer, 2019, 17, e549-e552.	0.9	5
693	Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. Prostate, 2019, 79, 701-708.	1.2	18
694	BRCA2 and Other DDR Genes in Prostate Cancer. Cancers, 2019, 11, 352.	1.7	72
695	Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset. European Urology, 2019, 76, 338-339.	0.9	1
696	Splicing Factors Have an Essential Role in Prostate Cancer Progression and Androgen Receptor Signaling. Biomolecules, 2019, 9, 131.	1.8	36

#	Article	IF	Citations
697	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-14.	1.5	23
698	Germline Testing for Men With Prostate Cancer: Navigating an Expanding New World of Genetic Evaluation for Precision Therapy and Precision Management. Journal of Clinical Oncology, 2019, 37, 1455-1459.	0.8	26
699	Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms. Breast Cancer Research and Treatment, 2019, 176, 165-170.	1.1	7
700	Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. Nature Communications, 2019, 10, 1635.	5.8	64
701	Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9008-9013.	3.3	108
702	Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. Endocrine-Related Cancer, 2019, 26, R31-R52.	1.6	49
703	Effectiveness of Platinum-Based Chemotherapy in Patients With Metastatic Prostate Cancer: Systematic Review and Meta-analysis. Clinical Genitourinary Cancer, 2019, 17, e627-e644.	0.9	17
704	Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. Endocrine Connections, 2019, 8, R10-R26.	0.8	33
705	PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2019, 37, 490-503.	0.8	255
706	PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers. European Urology, 2019, 76, 459-460.	0.9	5
707	Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. European Urology, 2019, 76, 452-458.	0.9	109
708	Importancia del radio-223 en la prÃ¡ctica hospitalaria. VisiÃ³n del oncÃ³logo mÃ©dico. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2019, 38, 106-111.	0.0	0
710	Biological Evolution of Castration-resistant Prostate Cancer. European Urology Focus, 2019, 5, 147-154.	1.6	71
711	The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer. Drugs, 2019, 79, 381-400.	4.9	23
712	Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. Cancer Treatment and Research Communications, 2019, 19, 100120.	0.7	10
713	The influence of BRCA2 mutation on localized prostate cancer. Nature Reviews Urology, 2019, 16, 281-290.	1.9	53
714	Current progress and questions in germline genetics of prostate cancer. Asian Journal of Urology, 2019, 6, 3-9.	0.5	11
715	Therapeutic implications of germline genetic findings in cancer. Nature Reviews Clinical Oncology, 2019, 16, 386-396.	12.5	39

#	Article	IF	Citations
716	Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer. Asian Journal of Urology, 2019, 6, 91-98.	0.5	6
718	Cases in Precision Medicine: The Role of Tumor and Germline Genetic Testing in Breast Cancer Management. Annals of Internal Medicine, 2019, 171, 925.	2.0	10
719	Case reports are a valuable resource in the era of genomic testing. AME Medical Journal, 2019, 4, 3-3.	0.4	0
720	Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. JCO Precision Oncology, 2019, 3, 1-13.	1.5	12
721	The treatment of neuroendocrine prostate cancer; current status and future directions. International Journal of Endocrine Oncology, 2019, 6, IJE18.	0.4	0
722	Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors. PLoS ONE, 2019, 14, e0224227.	1.1	6
723	Deep and sustained radiological response after MEK-RAF inhibition in HRAS mutant apocrine carcinoma of the scalp. European Journal of Cancer, 2019, 122, 9-11.	1.3	1
724	Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. JCO Precision Oncology, 2019, 3, 1-9.	1.5	47
725	Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer. Current Opinion in Oncology, 2019, 31, 247-255.	1.1	7
726	Advancements in the clinical management of upper tract urothelial carcinoma. Expert Review of Anticancer Therapy, 2019, 19, 1051-1060.	1.1	6
727	A New Era of Prostate Cancer Precision Medicine. Frontiers in Oncology, 2019, 9, 1263.	1.3	28
728	Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis. BMC Medical Genetics, 2019, 20, 191.	2.1	30
729	Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients. Scientific Reports, 2019, 9, 17808.	1.6	38
730	Germline genetics in localized prostate cancer. Current Opinion in Urology, 2019, 29, 326-333.	0.9	1
731	Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation. Chinese Medical Journal, 2019, 132, 3012-3014.	0.9	4
732	Clinical implications of genetic aberrations in metastatic prostate cancer. Current Opinion in Urology, 2019, 29, 319-325.	0.9	0
733	Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future. Current Opinion in Oncology, 2019, 31, 188-193.	1.1	5
734	Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications. Frontiers in Oncology, 2019, 9, 1287.	1.3	22

#	Article	IF	Citations
735	Poly (ADP-ribose) polymerase inhibitors combined with other small-molecular compounds for the treatment of ovarian cancer. Anti-Cancer Drugs, 2019, 30, 554-561.	0.7	2
736	Targeting the androgen receptor and overcoming resistance in prostate cancer. Current Opinion in Oncology, 2019, 31, 175-182.	1.1	36
737	Exceptional Response to ¹⁷⁷Lutetium Prostate-Specific Membrane Antigen in Prostate Cancer Harboring DNA Repair Defects. JCO Precision Oncology, 2019, 3, 1-5.	1.5	10
738	Prioritization of Therapy Options for a Patient With High Tumor Mutation Burden and Microsatellite Instability but No Clinical Benefit From Immunotherapy. JCO Precision Oncology, 2019, 3, 1-7.	1.5	1
739	Primer on Hereditary Cancer Predisposition Genes Included Within Somatic Next-Generation Sequencing Panels. JCO Precision Oncology, 2019, 3, 1-11.	1.5	6
740	Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis. JCO Precision Oncology, 2019, 3, 1-6.	1.5	14
741	Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. Prostate Cancer and Prostatic Diseases, 2019, 22, 59-65.	2.0	67
742	NPRL2 enhances autophagy and the resistance to Everolimus in castrationâ€resistant prostate cancer. Prostate, 2019, 79, 44-53.	1.2	33
743	Targeting NPRL2 to enhance the efficacy of Olaparib in castration-resistant prostate cancer. Biochemical and Biophysical Research Communications, 2019, 508, 620-625.	1.0	9
744	Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives. Clinical Genitourinary Cancer, 2019, 17, 79-87.	0.9	18
745	Treatment of Metastatic Prostate Cancer in 2018. JAMA Oncology, 2019, 5, 263.	3.4	16
746	Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. Prostate Cancer and Prostatic Diseases, 2019, 22, 406-410.	2.0	45
747	Rapid Next-Generation Sequencing Method for Prediction of Prostate Cancer Risks. Journal of Molecular Diagnostics, 2019, 21, 49-57.	1.2	2
748	An overview of translational prostate cancer cohorts for prognostic and predictive studies. Histopathology, 2019, 74, 161-170.	1.6	1
749	EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. Cancer Research, 2019, 79, 819-829.	0.4	52
750	Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test. Prostate Cancer and Prostatic Diseases, 2019, 22, 195-205.	2.0	39
751	BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2019, 9, 210-219.	7.7	278
752	Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. Prostate, 2019, 79, 333-339.	1.2	69

#	Article	IF	Citations
753	DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giantâ€cell features. Histopathology, 2019, 74, 836-843.	1.6	15
754	Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients. Breast Cancer Research and Treatment, 2019, 174, 639-647.	1.1	16
755	Circulating tumor DNA alterations in patients with metastatic castrationâ€resistant prostate cancer. Cancer, 2019, 125, 1459-1469.	2.0	38
756	Targeting DNA repair in precision medicine. Advances in Protein Chemistry and Structural Biology, 2019, 115, 135-155.	1.0	8
757	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. European Urology, 2019, 75, 667-675.	0.9	131
758	Cell death in cancer in the era of precision medicine. Genes and Immunity, 2019, 20, 529-538.	2.2	8
759	Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. Cancer Biology and Therapy, 2019, 20, 219-226.	1.5	30
760	Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Molecular Cancer Research, 2019, 17, 446-456.	1.5	44
761	Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. European Urology, 2019, 75, 184-192.	0.9	69
762	State-of-the-art strategies for targeting the DNA damage response in cancer. Nature Reviews Clinical Oncology, 2019, 16, 81-104.	12.5	736
763	Tumor cell heterogeneity and resistance; report from the 2018 Coffeyâ€Holden Prostate Cancer Academy Meeting. Prostate, 2019, 79, 244-258.	1.2	13
764	Long non-coding RNAs in prostate cancer: Biological and clinical implications. Molecular and Cellular Endocrinology, 2019, 480, 142-152.	1.6	12
765	Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. , 2019, , 1-14.		0
766	Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. Clinical Pharmacokinetics, 2019, 58, 615-625.	1.6	18
767	Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer. European Urology Oncology, 2019, 2, 1-11.	2.6	27
768	Plasma DNA Analysis in Prostate Cancer: Opportunities for Improving Clinical Management. Clinical Chemistry, 2019, 65, 100-107.	1.5	16
769	Earlyâ€onset colorectal cancer in young individuals. Molecular Oncology, 2019, 13, 109-131.	2.1	365
770	Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response. Prostate, 2019, 79, 390-402.	1.2	30

#	Article	IF	Citations
771	Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 535-542.	0.8	2
772	Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, earlyâ€onset disease. Cancer, 2019, 125, 1060-1069.	2.0	28
773	Synergistic Interactions: Targeted Radiopharmaceuticals and Homologous Recombination Repair Alterations in Prostate Cancer. European Urology, 2019, 76, 177-178.	0.9	1
774	PARP inhibition â€" not all gene mutations are created equal. Nature Reviews Urology, 2019, 16, 4-6.	1.9	17
775	Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer. Annual Review of Cancer Biology, 2019, 3, 235-254.	2.3	47
776	Targeting genotoxic and proteotoxic stressâ€response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram. Prostate, 2019, 79, 352-362.	1.2	23
777	Pathological Assessment of Prostate Cancer. , 2019, , 1-19.		0
778	Metastatic prostate cancer remains incurable, why?. Asian Journal of Urology, 2019, 6, 26-41.	0.5	103
779	Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. European Urology, 2019, 76, 170-176.	0.9	71
780	RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 687-697.	3.2	43
781	Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Research and Treatment, 2019, 173, 37-48.	1.1	205
782	Copenhagen Prospective Personalized Oncology (CoPPO)â€"Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials. Clinical Cancer Research, 2019, 25, 1239-1247.	3.2	59
783	Tumor Lysis Syndrome After Platinum-based Chemotherapy in Castration-resistant Prostate Cancer With a BRCA2 Mutation: A Case Report. Clinical Genitourinary Cancer, 2019, 17, e61-e64.	0.9	5
784	DNA repair defects in prostate cancer: impact for screening, prognostication and treatment. BJU International, 2019, 123, 769-776.	1.3	35
785	DNA Damage Response in Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a030486.	2.9	40
786	Fluorescence anisotropy imaging in drug discovery. Advanced Drug Delivery Reviews, 2019, 151-152, 262-288.	6.6	51
787	Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic Era. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a030528.	2.9	36
788	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. European Urology, 2019, 75, 88-99.	0.9	333

#	Article	IF	Citations
789	Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer. European Urology Focus, 2019, 5, 831-841.	1.6	11
790	Taxane-based Combination Therapies for Metastatic Prostate Cancer. European Urology Focus, 2019, 5, 369-380.	1.6	23
791	Role of the DNA damage response in prostate cancer formation, progression and treatment. Prostate Cancer and Prostatic Diseases, 2020, 23, 24-37.	2.0	37
792	Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer. International Journal of Cancer, 2020, 146, 487-495.	2.3	16
793	Germline Pathogenic Variants in 7636 Japanese Patients With Prostate Cancer and 12Â366 Controls. Journal of the National Cancer Institute, 2020, 112, 369-376.	3.0	69
794	Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men. European Urology Oncology, 2020, 3, 291-297.	2.6	14
795	Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. Expert Review of Molecular Diagnostics, 2020, 20, 219-230.	1.5	36
796	Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 1-10.	0.9	52
797	Screening, Active Surveillance, and Treatment of Localized Prostate Cancer Among Carriers of Germline BRCA Mutations. European Urology Focus, 2020, 6, 212-214.	1.6	9
798	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. Expert Review of Molecular Diagnostics, 2020, 20, 207-217.	1.5	5
799	Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations. Gynecologic Oncology, 2020, 156, 488-497.	0.6	51
800	Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. Oncologist, 2020, 25, e198-e202.	1.9	11
801	Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. European Urology, 2020, 77, 333-341.	0.9	65
802	Targeting DNA repair in cancer: current state and novel approaches. Cellular and Molecular Life Sciences, 2020, 77, 677-703.	2.4	65
803	Patients Resistant Against PSMA-Targeting Î±-Radiation Therapy Often Harbor Mutations in DNA Damage-Repairâ€“Associated Genes. Journal of Nuclear Medicine, 2020, 61, 683-688.	2.8	61
805	Synergism between ATM and PARP1 Inhibition Involves DNA Damage and Abrogating the G2 DNA Damage Checkpoint. Molecular Cancer Therapeutics, 2020, 19, 123-134.	1.9	30
806	How Do We Respond to Men with BRCA Mutations when They Ask About Prostate Cancer?. European Urology, 2020, 77, 36-37.	0.9	0
807	Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clinical Chemistry and Laboratory Medicine, 2020, 58, 326-339.	1.4	123

#	Article	IF	Citations
808	BRCA2 gene mutation and prostate cancer risk. Journal of King Abdulaziz University, Islamic Economics, 2020, 41, 9-17.	0.5	13
809	An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor. Oncologist, 2020, 25, e60-e67.	1.9	9
810	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. Oncologist, 2020, 25, 404-413.	1.9	25
811	Novel immunotherapy combinations for genitourinary cancers. Expert Opinion on Biological Therapy, 2020, 20, 253-262.	1.4	11
812	DNAâ€"protein cross-link repair: what do we know now?. Cell and Bioscience, 2020, 10, 3.	2.1	32
813	Genomics and the History of Precision Oncology. Surgical Oncology Clinics of North America, 2020, 29, 35-49.	0.6	23
815	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 83-93.	0.8	24
816	Inhibition of base excision repair by natamycin suppresses prostate cancer cell proliferation. Biochimie, 2020, 168, 241-250.	1.3	18
817	Noncanonical Wnt as a prognostic marker in prostate cancer: â€œyou canâ€™t always get what you Wntâ€. Expert Review of Molecular Diagnostics, 2020, 20, 245-254.	1.5	4
818	The Genomic and Molecular Pathology of Prostate Cancer: Clinical Implications for Diagnosis, Prognosis, and Therapy. Advances in Anatomic Pathology, 2020, 27, 11-19.	2.4	12
819	Chimeric Antigen Receptor T-cell Therapy in Prostate Cancer: Reality or Folly?. European Urology, 2020, 77, 309-310.	0.9	2
820	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clinical Cancer Research, 2020, 26, 1372-1384.	3.2	66
821	Circulating tumor cells and Î³H2AX as biomarkers for responsiveness to radium-223 in advanced prostate cancer patients. Future Science OA, 2020, 6, FSO437.	0.9	5
822	Extracellular vesicles in urological malignancies: an update. Nature Reviews Urology, 2020, 17, 11-27.	1.9	79
823	Prostate cancer research: The next generation; report from the 2019 Coffeyâ€Holden Prostate Cancer Academy Meeting. Prostate, 2020, 80, 113-132.	1.2	25
824	Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. British Journal of Cancer, 2020, 122, 333-339.	2.9	141
825	Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression. Clinical Cancer Research, 2020, 26, 2047-2064.	3.2	77
826	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. Journal of Clinical Oncology, 2020, 38, 406-414.	0.8	60

#	Article	IF	Citations
827	Delving into PARP inhibition from bench to bedside and back. , 2020, 206, 107446.		11
828	Current Approaches to Germline Cancer Genetic Testing. Annual Review of Medicine, 2020, 71, 85-102.	5.0	12
829	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 162-174.	5.1	450
830	Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials. Journal of Cancer Research and Clinical Oncology, 2020, 146, 721-737.	1.2	21
831	Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course. Gynecologic Oncology, 2020, 156, 415-422.	0.6	28
832	An Emerging Regulatory Role for the Tumor Microenvironment in the DNA Damage Response to Double-Strand Breaks. Molecular Cancer Research, 2020, 18, 185-193.	1.5	28
833	Germline variants and response to systemic therapy in advanced prostate cancer. Pharmacogenomics, 2020, 21, 75-81.	0.6	2
834	PARP1 Inhibition Augments UVB-Mediated Mitochondrial Changesâ€"Implications for UV-Induced DNA Repair and Photocarcinogenesis. Cancers, 2020, 12, 5.	1.7	36
835	Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. Journal of Hematology and Oncology, 2020, 13, 130.	6.9	166
836	New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 578095.	1.3	36
837	Patient selection biomarker strategies for PARP inhibitor therapy. Annals of Oncology, 2020, 31, 1603-1605.	0.6	7
838	Pathologic Complete Response in Patient With ATM Mutation After Neoadjuvant FOLFOXIRI Plus Panitumumab Therapy for Locally Advanced Colon Cancer: A Case Report. Clinical Colorectal Cancer, 2021, 20, e96-e99.	1.0	5
839	Epigenetic based synthetic lethal strategies in human cancers. Biomarker Research, 2020, 8, 44.	2.8	19
840	Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. Life Sciences, 2020, 261, 118434.	2.0	23
841	Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. PLoS ONE, 2020, 15, e0239686.	1.1	6
842	Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nature Communications, 2020, 11, 5259.	5.8	102
843	Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey. BMC Cancer, 2020, 20, 994.	1.1	10
844	The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer. Cancer Biology and Medicine, 2020, 17, 1002-1013.	1.4	18

#	Article	IF	Citations
845	Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing. Molecular Cancer, 2020, 19, 147.	7.9	50
846	Genetic biomarkers to guide poly(ADPâ€ribose) polymeraseÂinhibitor precision treatment of prostate cancer. Pharmacogenomics, 2020, 21, 1101-1115.	0.6	0
847	Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data. Targeted Oncology, 2020, 15, 709-722.	1.7	17
848	Precision Oncology for Metastatic Prostate Cancer: Translation into Practice. European Urology, 2020, 78, 771-774.	0.9	3
849	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology, 2020, 31, 1491-1505.	0.6	658
850	A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 5092-5101.	3.2	28
851	Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. International Journal of Molecular Sciences, 2020, 21, 5036.	1.8	38
852	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. Annals of Oncology, 2020, 31, 1135-1147.	0.6	58
853	Genomic Profiling of Prostate Cancers from Men with African and European Ancestry. Clinical Cancer Research, 2020, 26, 4651-4660.	3.2	68
854	Case Report: Co-Existence of BRCA2 and PALB2 Germline Mutations in Familial Prostate Cancer With Solitary Lung Metastasis. Frontiers in Oncology, 2020, 10, 564694.	1.3	6
855	Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort. Scientific Reports, 2020, 10, 20223.	1.6	15
856	Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Cancers, 2020, 12, 3467.	1.7	13
857	A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?. European Urology Oncology, 2021, 4, 745-754.	2.6	17
858	Germline Genetic Findings Which May Impact Therapeutic Decisions in Families with a Presumed Predisposition for Hereditary Breast and Ovarian Cancer. Cancers, 2020, 12, 2151.	1.7	5
859	Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant. Npj Breast Cancer, 2020, 6, 31.	2.3	13
860	The emerging role of PARP inhibitors in prostate cancer. Expert Review of Anticancer Therapy, 2020, 20, 715-726.	1.1	12
861	Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment. BMC Cancer, 2020, 20, 748.	1.1	36
862	The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs. Nature Reviews Urology, 2020, 17, 499-512.	1.9	15

#	Article	IF	Citations
863	The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapyâ€“Current progress and future direction. European Journal of Medicinal Chemistry, 2020, 203, 112570.	2.6	45
864	Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial. JCO Precision Oncology, 2020, 4, 882-897.	1.5	22
865	Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas. Theranostics, 2020, 10, 9477-9494.	4.6	19
866	Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer. Cancer Science, 2020, 111, 3111-3121.	1.7	43
867	Racial Disparity in Response to Prostate Cancer Systemic Therapies. Current Oncology Reports, 2020, 22, 96.	1.8	11
868	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. Journal of Clinical Oncology, 2020, 38, 3763-3772.	0.8	448
869	Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2020, 10, 581515.	1.3	27
870	Alterations of DNA damage response genes correlate with response and overall survival in antiâ€PDâ€1/PDâ€L1â€treated advanced urothelial cancer. Cancer Medicine, 2020, 9, 9365-9372.	1.3	16
871	Novel therapies are changing treatment paradigms in metastatic prostate cancer. Journal of Hematology and Oncology, 2020, 13, 144.	6.9	80
872	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal of Clinical Oncology, 2020, 38, 4274-4282.	0.8	276
873	The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer. Cells, 2020, 9, 2342.	1.8	34
874	Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer. Journal of Experimental Medicine, 2020, 217, .	4.2	19
875	BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?. Journal of Clinical Oncology, 2020, 38, 3735-3739.	0.8	38
876	Immunotherapy in prostate cancer: current state and future perspectives. Therapeutic Advances in Urology, 2020, 12, 175628722095140.	0.9	24
877	BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. Journal of Oncology, 2020, 2020, 1-7.	0.6	58
878	PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date . Cancer Management and Research, 2020, Volume 12, 8105-8114.	0.9	58
879	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2020, 383, 2345-2357.	13.9	440
880	The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers. International Journal of Gynecological Cancer, 2020, 30, 1608-1618.	1.2	4

#	Article	IF	Citations
881	Genetic profiling of primary and secondary tumors from patients with lung adenocarcinoma and bone metastases reveals targeted therapy options. Molecular Medicine, 2020, 26, 88.	1.9	11
882	Olaparib for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2020, 383, 890-891.	13.9	9
883	Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer. Cancer Biology and Therapy, 2020, 21, 884-887.	1.5	2
884	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate, 2020, 80, 1273-1296.	1.2	16
885	Germline mutations and prostate cancer: is it time to change treatment algorithms?. Chinese Clinical Oncology, 2020, 9, 65-65.	0.4	2
886	Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment. Journal of Clinical Oncology, 2020, 38, 3740-3742.	0.8	14
887	Feasibility and performance of a novel probe panel to detect somatic DNA copy number alterations in clinical specimens for predicting prostate cancer progression. Prostate, 2020, 80, 1253-1262.	1.2	4
888	PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Frontiers in Cell and Developmental Biology, 2020, 8, 564601.	1.8	315
889	ACK1â€“AR and ARâ€“HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers. NAR Cancer, 2020, 2, zcaa018.	1.6	22
891	Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine, 2020, 59, 102923.	2.7	22
892	When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials. European Urology Oncology, 2020, 3, 594-611.	2.6	63
893	Targeting defective DNA repair in prostate cancer. Current Opinion in Oncology, 2020, 32, 503-509.	1.1	4
894	Metastatic Castration-Resistant Prostate Cancer with Neuroendocrine Transformation and BRCA 1 Germ-Line Mutation: A Case Report and Literature Review . OncoTargets and Therapy, 2020, Volume 13, 8049-8054.	1.0	8
895	Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer. Cancers, 2020, 12, 3756.	1.7	4
896	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. JCO Precision Oncology, 2020, 4, 1350-1360.	1.5	18
897	Pan-cancer landscape of homologous recombination deficiency. Nature Communications, 2020, 11, 5584.	5.8	262
898	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Network Open, 2020, 3, e2021692.	2.8	70
899	Clinical implications of genomic evaluations for prostate cancer risk stratification, screening, and treatment: a narrative review. Prostate International, 2020, 8, 99-106.	1.2	16

#	Article	IF	Citations
900	Clinical Trials in Metastatic Uveal Melanoma: Current Status. Ocular Oncology and Pathology, 2020, 6, 381-387.	0.5	16
901	Targeting DNA Damage Response in Prostate and Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 8273.	1.8	50
902	RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational Status. Cancers, 2020, 12, 3178.	1.7	10
903	Harnessing the potential of multimodal radiotherapy in prostate cancer. Nature Reviews Urology, 2020, 17, 321-338.	1.9	15
904	Therapeutic targeting of the DNA damage response in prostate cancer. Current Opinion in Oncology, 2020, 32, 216-222.	1.1	11
905	Therapeutic applications of PARP inhibitors in ovarian cancer. Biomedicine and Pharmacotherapy, 2020, 127, 110204.	2.5	29
906	BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects . Cancer Management and Research, 2020, Volume 12, 2731-2742.	0.9	69
907	PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review. Prostate Cancer and Prostatic Diseases, 2020, 23, 549-560.	2.0	36
908	Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. JCO Precision Oncology, 2020, 4, 442-465.	1.5	103
909	Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer. Cancer Immunology Research, 2020, 8, 844-850.	1.6	12
910	Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castrationâ€resistant prostate cancer: Realâ€world experience in the Southeast Asian cohort. Cancer Medicine, 2020, 9, 4613-4621.	1.3	4
911	BRCA testing in a genomic diagnostics referral center during the COVID-19 pandemic. Molecular Biology Reports, 2020, 47, 4857-4860.	1.0	22
912	Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential. BMC Cancer, 2020, 20, 398.	1.1	13
913	Emerging Subtypes and New Treatments for Castration-Resistant Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e319-e332.	1.8	3
914	The Changing Landscape of Upper Tract Urothelial Carcinoma Management. Urology, 2020, 145, 316-318.	0.5	0
915	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. Clinical Chemistry, 2020, 66, 842-851.	1.5	25
916	Genomics-guided pre-clinical development of cancer therapies. Nature Cancer, 2020, 1, 482-492.	5.7	23
917	Pharmacotherapeutic strategies for castrate-resistant prostate cancer. Expert Opinion on Pharmacotherapy, 2020, 21, 1431-1448.	0.9	23

#	Article	IF	Citations
918	Integrating Genetic and Genomic Testing Into Oncology Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e259-e263.	1.8	6
919	Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer. Current Opinion in Urology, 2020, 30, 519-526.	0.9	15
920	Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors. Frontiers in Oncology, 2020, 10, 570.	1.3	127
921	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. American Journal of Surgical Pathology, 2020, 44, e15-e29.	2.1	40
922	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. Cancers, 2020, 12, 1502.	1.7	145
923	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Nonâ€“BRCA1/2-Mutant Cancers. Cancer Discovery, 2020, 10, 1528-1543.	7.7	82
924	PARP inhibitors in prostate cancer: time to narrow patient selection?. Expert Review of Anticancer Therapy, 2020, 20, 523-526.	1.1	4
925	PARP inhibitor resistance: the underlying mechanisms and clinical implications. Molecular Cancer, 2020, 19, 107.	7.9	235
926	Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. Carcinogenesis, 2020, 41, 904-908.	1.3	1
927	Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. BMC Cancer, 2020, 20, 507.	1.1	48
928	ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738. Genome Instability & Disease, 2020, 1, 197-205.	0.5	9
929	Assessment of PARP-1 Distribution in Tissues of Cynomolgus Monkeys. Journal of Histochemistry and Cytochemistry, 2020, 68, 413-435.	1.3	4
930	DNA Damage Repair Deficiency in Prostate Cancer. Trends in Cancer, 2020, 6, 974-984.	3.8	25
931	Clinical Applications of Molecular Biomarkers in Prostate Cancer. Cancers, 2020, 12, 1550.	1.7	21
932	Urupocidin C: a new marine guanidine alkaloid which selectively kills prostate cancer cells via mitochondria targeting. Scientific Reports, 2020, 10, 9764.	1.6	18
933	Pharmacological management of male breast cancer. Expert Opinion on Pharmacotherapy, 2020, 21, 1493-1504.	0.9	3
934	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 2020, 38, 2798-2811.	0.8	170
935	Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review. International Journal of Molecular Sciences, 2020, 21, 4327.	1.8	22

#	Article	IF	Citations
936	How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors. Therapeutic Advances in Medical Oncology, 2020, 12, 175883591989753.	1.4	8
937	Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nature Reviews Urology, 2020, 17, 271-291.	1.9	32
938	Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report. BMC Cancer, 2020, 20, 215.	1.1	30
939	The challenge of checkpoint inhibitors in prostate cancer: drugs for the many but useful to a few. Immunotherapy, 2020, 12, 219-221.	1.0	0
940	Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer. Oncologist, 2020, 25, e1042-e1050.	1.9	17
941	Intratumoral heterogeneity and genetic characteristics of prostate cancer. International Journal of Cancer, 2020, 146, 3369-3378.	2.3	29
942	Olaparib and enzalutamide synergistically suppress HCC progression via the ARâ€mediated miRâ€146aâ€5p/BRCA1 signaling. FASEB Journal, 2020, 34, 5877-5891.	0.2	9
943	Knowing whatâ€™s growing: Why ductal and intraductal prostate cancer matter. Science Translational Medicine, 2020, 12, .	5.8	27
944	SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. Molecular Cancer Therapeutics, 2020, 19, 1157-1164.	1.9	44
945	Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition. Cancer Research, 2020, 80, 3033-3045.	0.4	23
946	ATM-Deficient Cancers Provide New Opportunities for Precision Oncology. Cancers, 2020, 12, 687.	1.7	76
947	Inherited DNA Repair Gene Mutations in Men with Lethal Prostate Cancer. Genes, 2020, 11, 314.	1.0	16
948	Cancer Genetics and Therapeutic Opportunities in Urologic Practice. Cancers, 2020, 12, 710.	1.7	3
949	Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes. Journal of Clinical Oncology, 2020, 38, 1807-1813.	0.8	27
951	68Ga-PSMAâ€“Guided Bone Biopsies for Molecular Diagnostics in Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 1607-1614.	2.8	11
952	Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy. Frontiers in Pharmacology, 2020, 11, 170.	1.6	57
953	Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations. Clinical Cancer Research, 2020, 26, 2673-2680.	3.2	64
954	Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report. Case Reports in Oncology, 2020, 13, 55-61.	0.3	3

#	Article	IF	Citations
955	Olaparib Potentiates Anticancer Drug Cytotoxicity via 53BP1 in Oesophageal Squamous Cell Carcinoma Cells. Anticancer Research, 2020, 40, 813-823.	0.5	7
956	PARP Inhibitors in Prostate and Urothelial Cancers. Frontiers in Oncology, 2020, 10, 114.	1.3	13
957	Resistance mechanisms to taxanes and PARP inhibitors in advanced prostate cancer. Current Opinion in Endocrine and Metabolic Research, 2020, 10, 16-22.	0.6	8
958	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2020, 31, 1119-1134.	0.6	485
959	Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer. European Journal of Cancer, 2020, 136, 16-24.	1.3	41
960	Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer. Memo - Magazine of European Medical Oncology, 2020, 13, 371-374.	0.3	1
961	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. Cells, 2020, 9, 1495.	1.8	8
962	Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors. Leukemia, 2020, 34, 2992-3006.	3.3	14
963	Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. EBioMedicine, 2020, 54, 102728.	2.7	65
964	New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. Cells, 2020, 9, 1522.	1.8	6
965	The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. Trials, 2020, 21, 579.	0.7	16
966	Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17785-17795.	3.3	27
967	Malignancies in immune deficiencies. , 2020, , 1079-1096.		0
969	PARP and PARG inhibitors in cancer treatment. Genes and Development, 2020, 34, 360-394.	2.7	360
970	What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing. Prostate, 2020, 80, 441-450.	1.2	8
971	Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib. Oncologist, 2020, 25, 301-305.	1.9	9
972	Immunotherapy for castration-resistant prostate cancer: has its time arrived?. Expert Opinion on Biological Therapy, 2020, 20, 481-487.	1.4	10
973	Axons Matter: The Promise of Treating Neurodegenerative Disorders by Targeting SARM1-Mediated Axonal Degeneration. Trends in Pharmacological Sciences, 2020, 41, 281-293.	4.0	82

#	Article	IF	Citations
974	Genetic Profile and Functional Proteomics of Anal Squamous Cell Carcinoma: Proposal for a Molecular Classification. Molecular and Cellular Proteomics, 2020, 19, 690-700.	2.5	4
975	Genomics to personalize care of prostate cancer. Journal of the American Association of Nurse Practitioners, 2020, 32, 106-108.	0.5	1
976	A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity. Nature Communications, 2020, 11, 822.	5.8	62
977	BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo. International Journal of Biological Macromolecules, 2020, 150, 238-245.	3.6	9
978	A phase I dose-escalation study of enzalutamide in combination with theÂAKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. Annals of Oncology, 2020, 31, 619-625.	0.6	54
979	Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 5269-5279.	3.3	44
980	Using nextâ€generation sequencing to redefine BRCAness in tripleâ€negative breast cancer. Cancer Science, 2020, 111, 1375-1384.	1.7	35
981	The antitumorigenic roles of BRCA1â€“BARD1 in DNA repair and replication. Nature Reviews Molecular Cell Biology, 2020, 21, 284-299.	16.1	199
982	Genomic Strategies to Personalize Use of Androgen Deprivation Therapy With Radiotherapy. Cancer Journal (Sudbury, Mass), 2020, 26, 13-20.	1.0	1
983	Mutational and transcriptomic landscapes of a rare human prostate basal cell carcinoma. Prostate, 2020, 80, 508-517.	1.2	12
984	Flawed trials for cancer. Annals of Oncology, 2020, 31, 331-333.	0.6	5
985	Cancer transcriptomic profiling from rapidly enriched circulating tumor cells. International Journal of Cancer, 2020, 146, 2845-2854.	2.3	7
986	Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 2546-2555.	3.2	33
987	Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches. Cancer Treatment and Research Communications, 2020, 23, 100164.	0.7	22
988	Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy. Future Oncology, 2020, 16, 75-80.	1.1	11
989	Genetic Testing in Prostate Cancer. Current Oncology Reports, 2020, 22, 5.	1.8	25
990	Circulating cell-free DNA: Translating prostate cancer genomics into clinical care. Molecular Aspects of Medicine, 2020, 72, 100837.	2.7	6
991	Enabling Precision Oncology Through Precision Diagnostics. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 97-121.	9.6	50

#	Article	IF	Citations
992	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	0.9	278
993	Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report. Diagnostic Pathology, 2020, 15, 5.	0.9	7
994	Biomarkers of response to advanced prostate cancer therapy. Expert Review of Molecular Diagnostics, 2020, 20, 195-205.	1.5	12
995	Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. European Urology Oncology, 2020, 3, 224-230.	2.6	41
996	The Emerging Role of Local Therapy in Metastatic Prostate Cancer. Current Oncology Reports, 2020, 22, 2.	1.8	7
997	PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation. Journal of Radiation Research, 2020, 61, 177-186.	0.8	14
998	Olaparib for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2020, 382, 2091-2102.	13.9	1,327
999	Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells. Cell Death and Disease, 2020, 11, 219.	2.7	14
1000	Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 2032-2042.	3.3	85
1001	Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy. Cancers, 2020, 12, 972.	1.7	14
1002	Prevalence and Spectrum of Pathogenic Germline Variants in Japanese Patients With Early-Onset Colorectal, Breast, and Prostate Cancer. JCO Precision Oncology, 2020, 4, 183-191.	1.5	6
1003	The genetic landscapes of urological cancers and their clinical implications in the era of highâ€throughput genome analysis. BJU International, 2020, 126, 26-54.	1.3	5
1004	Rare germline genetic variants and risk of aggressive prostate cancer. International Journal of Cancer, 2020, 147, 2142-2149.	2.3	12
1005	ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. Cancer Research, 2020, 80, 2094-2100.	0.4	71
1006	Germline and somatic DNA repair gene alterations in prostate cancer. Cancer, 2020, 126, 2980-2985.	2.0	24
1008	Toward a More Precise Future for Oncology. Cancer Cell, 2020, 37, 431-442.	7.7	21
1009	Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians. Oncogene, 2020, 39, 4299-4311.	2.6	30
1010	Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis. Medicine (United States), 2020, 99, e19760.	0.4	34

#	Article	IF	Citations
1011	Mainstream consent programs for genetic counseling in cancer patients: A systematic review. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 163-177.	0.7	29
1012	Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk,) Tj ETQq1 1 0.784314 rgBT /Overlock	0.4	12
1013	Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors. Cancer Research, 2020, 80, 2427-2436.	0.4	54
1014	An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer. Molecular Cancer Therapeutics, 2020, 19, 1373-1382.	1.9	20
1015	Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. JCO Precision Oncology, 2020, 4, 355-366.	1.5	93
1016	CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precision Oncology, 2020, 4, 370-381.	1.5	138
1017	Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. Clinical Cancer Research, 2020, 26, 2487-2496.	3.2	273
1018	PARP inhibitor combinations in prostate cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883591989753.	1.4	21
1019	Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets. Frontiers in Cell and Developmental Biology, 2020, 8, 160.	1.8	46
1020	Molecular Trajectory of BRCA1 and BRCA2 Mutations. Frontiers in Oncology, 2020, 10, 361.	1.3	31
1021	High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naÃ¯ve metastatic prostate cancer â€“Results from a prospective pilot study using a 37 gene panel. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e17-637.e27.	0.8	12
1022	Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 312-315.	0.8	9
1023	PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias. Blood Reviews, 2021, 45, 100696.	2.8	17
1024	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2021, 145, 461-493.	1.2	143
1025	FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer. Oncologist, 2021, 26, 139-146.	1.9	42
1026	Survey of palliative care providersâ€™ needs, perceived roles, and ethical concerns about addressing cancer family history at the end of life. Palliative and Supportive Care, 2021, 19, 217-222.	0.6	2
1027	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. European Urology, 2021, 79, 200-211.	0.9	76
1028	Tracking the expression of therapeutic protein targets in rare cells by antibody-mediated nanoparticle labelling and magnetic sorting. Nature Biomedical Engineering, 2021, 5, 41-52.	11.6	40

#	Article	IF	Citations
1029	Prevalence of comprehensive <scp>DNA</scp> damage repair gene germline mutations in Chinese prostate cancer patients. International Journal of Cancer, 2021, 148, 673-681.	2.3	20
1030	Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. European Urology, 2021, 79, 442-445.	0.9	41
1031	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part IIâ€"2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology, 2021, 79, 263-282.	0.9	633
1032	Re: Olaparib for Metastatic Castration-resistant Prostate Cancer. European Urology, 2021, 79, 319-320.	0.9	0
1033	<scp>PARP</scp> inhibition in prostate cancer. Genes Chromosomes and Cancer, 2021, 60, 344-351.	1.5	2
1034	DNA Damage Repair Deficiency and Synthetic Lethality for Cancer Treatment. Trends in Molecular Medicine, 2021, 27, 91-92.	3.5	14
1035	Combinatorial Approaches to Enhance DNA Damage following Enzyme-Mediated Depletion of L-Cys for Treatment of Pancreatic Cancer. Molecular Therapy, 2021, 29, 775-787.	3.7	8
1036	CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage. Prostate, 2021, 81, 81-88.	1.2	9
1037	Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Annals of Oncology, 2021, 32, 240-249.	0.6	115
1038	To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?. Expert Review of Anticancer Therapy, 2021, 21, 389-400.	1.1	2
1039	Analysis of mutational signatures with yet another package for signature analysis. Genes Chromosomes and Cancer, 2021, 60, 314-331.	1.5	40
1040	Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. Critical Reviews in Oncology/Hematology, 2021, 157, 103185.	2.0	41
1041	Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies. Prostate Cancer and Prostatic Diseases, 2021, 24, 301-309.	2.0	19
1042	Molecular pathology of prostate cancer: a practical approach. Pathology, 2021, 53, 36-43.	0.3	17
1043	Novel Agents and Future Perspectives on Theranostics. Seminars in Radiation Oncology, 2021, 31, 83-92.	1.0	9
1044	The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. Critical Reviews in Oncology/Hematology, 2021, 157, 103199.	2.0	16
1045	Considerations for designing preclinical cancer immune nanomedicine studies. Nature Nanotechnology, 2021, 16, 6-15.	15.6	77
1046	BRCA testing delay during the COVID-19 pandemic: How to act?. Molecular Biology Reports, 2021, 48, 983-987.	1.0	7

#	Article	IF	Citations
1047	Treatment and resistance mechanisms in castration-resistant prostate cancer: new implications for clinical decision making?. Expert Review of Anticancer Therapy, 2021, 21, 149-163.	1.1	4
1048	Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer. JCO Oncology Practice, 2021, 17, e204-e216.	1.4	27
1049	Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. British Journal of Cancer, 2021, 124, 552-563.	2.9	63
1050	PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCA. Oncologist, 2021, 26, e115-e129.	1.9	51
1051	Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer. Journal of the National Cancer Institute, 2021, 113, 616-625.	3.0	40
1052	Efficacy of Novel Bromodomain and Extraterminal Inhibitors in Combination with Chemotherapy for Castration-Resistant Prostate Cancer. European Urology Oncology, 2021, 4, 437-446.	2.6	10
1053	The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families. Journal of Cancer Education, 2021, 36, 72-84.	0.6	13
1054	Navigating systemic therapy for metastatic castration-naÃ¨ve prostate cancer. World Journal of Urology, 2021, 39, 339-348.	1.2	11
1055	Integrated Analysis of Mutations and Dysregulated Pathways Unravels Carcinogenic Effect and Clinical Actionability of Mutational Processes. SSRN Electronic Journal, 0, , .	0.4	0
1056	Inflammation Mediates the Development of Aggressive Breast Cancer Following Radiotherapy. Clinical Cancer Research, 2021, 27, 1778-1791.	3.2	13
1057	Tumor Profiling at the Service of Cancer Therapy. Frontiers in Oncology, 2020, 10, 595613.	1.3	9
1058	Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy. Asian Journal of Andrology, 2022, 24, 116.	0.8	3
1059	Genetic predisposition to prostate cancer: an update. Familial Cancer, 2022, 21, 101-114.	0.9	18
1060	Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer. Cancer Research, 2021, 81, 1583-1594.	0.4	140
1061	Fast mutual exclusivity algorithm nominates potential synthetic lethal gene pairs through brute force matrix product computations. Computational and Structural Biotechnology Journal, 2021, 19, 4394-4403.	1.9	5
1062	DNA Damage Repair Inhibitor for Breast Cancer Treatment. Advances in Experimental Medicine and Biology, 2021, 1187, 159-179.	0.8	0
1063	Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. Modern Pathology, 2021, 34, 1185-1193.	2.9	61
1064	Development of novel androgen receptor inhibitors to overcome castrate-resistant prostate cancer. , 2021, , 23-46.		0

#	Article	IF	Citations
1065	Comprehensive Genomic Profiling-Guided Niraparib Treatment of Triple-Negative Breast Cancer in a Patient With Extensive Brain Metastasis: Case Report and Literature Review. Journal of Immunotherapy and Precision Oncology, 2021, 4, 16-20.	0.6	1
1066	Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. JAMA Oncology, 2021, 7, 107.	3.4	90
1067	The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer. Breast Cancer Research and Treatment, 2021, 185, 869-877.	1.1	2
1068	Genomic Landscapes of Acral Melanomas in East Asia. Cancer Genomics and Proteomics, 2021, 18, 83-92.	1.0	6
1069	CHEK2 mutation in a patient with pancreatic adenocarcinomaâ€”a rare case report. AME Case Reports, 2021, 5, 5-5.	0.2	3
1070	Prevalence and spectrum of pathogenic germline variants in intestinal and pancreatobiliary type of ampullary cancer. Pathology Research and Practice, 2021, 217, 153309.	1.0	4
1071	Novel Metabolic Signatures of Prostate Cancer Revealed by 1H-NMR Metabolomics of Urine. Diagnostics, 2021, 11, 149.	1.3	22
1072	The Role of Androgen Receptor Splicing Variant 7 in Predicting the Prognosis of Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis. Technology in Cancer Research and Treatment, 2021, 20, 153303382110352.	0.8	8
1073	Finding the optimal treatment sequence in metastatic castration-resistant prostate cancerâ€”a narrative review. Translational Andrology and Urology, 2021, 10, 3931-3945.	0.6	3
1074	PSMA-targeted arsenic nanosheets: a platform for prostate cancer therapyviaferroptosis and ATM deficiency-triggered chemosensitization. Materials Horizons, 2021, 8, 2216-2229.	6.4	12
1075	Clinical implications of genomic alterations in metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 310-322.	2.0	12
1076	SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). Clinical and Translational Oncology, 2021, 23, 969-979.	1.2	18
1077	Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 786-793.	2.0	4
1078	5-HT7 receptors as a new target for prostate cancer physiopathology and treatment: an experimental study on PC-3 cells and FFPE tissues. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 1205-1213.	1.4	9
1079	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. Journal of Pathology: Clinical Research, 2021, 7, 311-325.	1.3	19
1080	Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation. Cancers, 2021, 13, 1004.	1.7	28
1081	Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. European Urology Oncology, 2021, 4, 1-9.	2.6	27
1082	Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer. Prostate, 2021, 81, 318-325.	1.2	7

#	Article	IF	Citations
1083	Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies. Cancer Reports, 2021, 4, e1340.	0.6	13
1084	Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. Clinical Cancer Research, 2021, 27, 3094-3105.	3.2	101
1085	Prostate cancer. Nature Reviews Disease Primers, 2021, 7, 9.	18.1	434
1086	Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer. Acta Pharmacologica Sinica, 2021, 42, 1970-1980.	2.8	4
1087	Apoptosis-Inducing Activity and Antiproliferative Effect of Gossypin on PC-3 Prostate Cancer Cells. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, 445-450.	0.9	12
1088	Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease. Cancers, 2021, 13, 760.	1.7	22
1089	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 134-143.	2.3	299
1090	Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer. Current Oncology Reports, 2021, 23, 59.	1.8	9
1091	Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand. Oncogene, 2021, 40, 3001-3014.	2.6	49
1092	Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024. European Urology, 2021, 79, e83-e84.	0.9	0
1093	Differential treatment outcomes in BRCA1/2â€, CDK12â€, and ATMâ€mutated metastatic castrationâ€resistant prostate cancer. Cancer, 2021, 127, 1965-1973.	2.0	15
1094	Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). Cancer Chemotherapy and Pharmacology, 2021, 88, 25-37.	1.1	19
1095	UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers, 2021, 13, 1566.	1.7	30
1096	Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers. Translational Oncology, 2021, 14, 101012.	1.7	26
1097	Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion. JCO Precision Oncology, 2021, 5, 533-542.	1.5	6
1098	Resistance to second-generation androgen receptor antagonists in prostate cancer. Nature Reviews Urology, 2021, 18, 209-226.	1.9	59
1099	A first Japanese case of BRCA2 and RB1 co-loss organ-confined prostate cancer successfully treated by radical prostatectomy. International Cancer Conference Journal, 2021, 10, 170-173.	0.2	1
1100	Histologyâ€based molecular profiling improves mutation detection for advanced thyroid cancer. Genes Chromosomes and Cancer, 2021, 60, 531-545.	1.5	5

#	Article	IF	Citations
1101	Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma. Molecular Cancer Research, 2021, 19, 991-1004.	1.5	19
1102	Rare Germline Pathogenic Variants Identified by Multigene Panel Testing and the Risk of Aggressive Prostate Cancer. Cancers, 2021, 13, 1495.	1.7	12
1103	Current Status and Future Targeted Therapy in Adrenocortical Cancer. Frontiers in Endocrinology, 2021, 12, 613248.	1.5	22
1104	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. Clinical Cancer Research, 2021, 27, 3234-3242.	3.2	24
1105	Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment. Oncologist, 2021, 26, 537-548.	1.9	8
1106	Olaparib in Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2021, 384, 1174-1176.	13.9	1
1107	Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development. Nature Reviews Clinical Oncology, 2021, 18, 454-467.	12.5	11
1108	Identification of a DNA Repair Gene Signature and Establishment of a Prognostic Nomogram Predicting Biochemical-Recurrence-Free Survival of Prostate Cancer. Frontiers in Molecular Biosciences, 2021, 8, 608369.	1.6	8
1109	Routine application of next-generation sequencing testing in uro-oncologyâ€"Are we ready for the next step of personalised medicine?. European Journal of Cancer, 2021, 146, 1-10.	1.3	5
1110	Prostate cancer and PARP inhibitors: progress and challenges. Journal of Hematology and Oncology, 2021, 14, 51.	6.9	68
1111	Clinical cancer genomic profiling. Nature Reviews Genetics, 2021, 22, 483-501.	7.7	79
1113	Targeting pan-essential genes in cancer: Challenges and opportunities. Cancer Cell, 2021, 39, 466-479.	7.7	88
1114	A Systematic Strategy of Combinational Blow for Overcoming Cascade Drug Resistance via NIRâ€Lightâ€Triggered Hyperthermia. Advanced Materials, 2021, 33, e2100599.	11.1	78
1115	Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?. International Journal of Molecular Sciences, 2021, 22, 4712.	1.8	14
1116	Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management. Cancers, 2021, 13, 2154.	1.7	13
1117	Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer. Expert Opinion on Pharmacotherapy, 2021, 22, 1625-1632.	0.9	5
1118	Which Way to Choose for the Treatment of Metastatic Prostate Cancer: A Case Report and Literature Review. Frontiers in Oncology, 2021, 11, 659442.	1.3	3
1119	Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention. International Journal of Molecular Sciences, 2021, 22, 3753.	1.8	61

#	Article	IF	Citations
1120	Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. European Urology, 2021, 79, 519-529.	0.9	30
1121	Transient Response of Olaparib on Pulmonary Artery Sarcoma Harboring Multiple Homologous Recombinant Repair Gene Alterations. Journal of Personalized Medicine, 2021, 11, 357.	1.1	3
1122	Changing the History of Prostate Cancer with New Targeted Therapies. Biomedicines, 2021, 9, 392.	1.4	16
1123	Resistance to the Androgen Receptor Centred Therapies: Biology and Management. SN Comprehensive Clinical Medicine, 2021, 3, 1593-1609.	0.3	0
1124	Clinical significance of mutations in DNA repair genes in patients with metastatic prostate cancer. Onkourologiya, 2021, 17, 82-88.	0.1	0
1125	Genetic alterations and their therapeutic implications in epithelial ovarian cancer. BMC Cancer, 2021, 21, 499.	1.1	27
1126	Flightless I Homolog Reverses Enzalutamide Resistance through PD-L1â€“Mediated Immune Evasion in Prostate Cancer. Cancer Immunology Research, 2021, 9, 838-852.	1.6	12
1127	Current State of Personalized Genitourinary Cancer Radiotherapy in the Era of Precision Medicine. Frontiers in Oncology, 2021, 11, 675311.	1.3	6
1128	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer Discovery, 2021, 11, 2812-2827.	7.7	78
1129	Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer. BMC Cancer, 2021, 21, 611.	1.1	5
1130	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nature Communications, 2021, 12, 2487.	5.8	116
1131	Immune Checkpoint Inhibitors in Prostate Cancer. Cancers, 2021, 13, 2187.	1.7	48
1132	Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice. JCO Precision Oncology, 2021, 5, 884-895.	1.5	21
1133	Prognostic Value of BRCA1 and BRCA2 Gene Mutations in Prostate Cancer: a Literature Review. KreativnaÃ¢ HirurgiÃ¢ I OnkologiÃ¢, 2021, 11, 183-187.	0.1	1
1134	Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology. Expert Opinion on Therapeutic Targets, 2021, 25, 329-333.	1.5	39
1136	2020 Korean guidelines for the management of metastatic prostate cancer. Korean Journal of Internal Medicine, 2021, 36, 491-514.	0.7	5
1138	Sleep disorders and prostate cancer prognosis. European Journal of Cancer Prevention, 2021, Publish Ahead of Print, .	0.6	3
1139	A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer. The Application of Clinical Genetics, 2021, Volume 14, 255-266.	1.4	0

#	Article	IF	Citations
1140	Discovery of primary prostate cancer biomarkers using cross cancer learning. Scientific Reports, 2021, 11, 10433.	1.6	19
1141	Adenocarcinoma of the Prostate: Future Directions for Translational Science. , 0, , 97-112.		0
1142	Downregulation of ATM and BRCA1 Predicts Poor Outcome in Head and Neck Cancer: Implications for ATM-Targeted Therapy. Journal of Personalized Medicine, 2021, 11, 389.	1.1	5
1143	Estrogen enhances the cytotoxicity of PARP inhibitors on breast cancer cells through stimulating nitric oxide production. Journal of Steroid Biochemistry and Molecular Biology, 2021, 209, 105853.	1.2	8
1144	The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials. Biomolecules, 2021, 11, 722.	1.8	9
1145	Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer. Nuclear Medicine and Biology, 2021, 96-97, 101-111.	0.3	10
1146	MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer. Cancers, 2021, 13, 2380.	1.7	12
1147	Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer. Current Molecular Pharmacology, 2021, 14, .	0.7	3
1148	An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers. Cancers, 2021, 13, 3113.	1.7	0
1149	Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells. International Journal of Molecular Sciences, 2021, 22, 6676.	1.8	5
1150	Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e190-e202.	1.8	9
1151	Novel insights in cell cycle dysregulation during prostate cancer progression. Endocrine-Related Cancer, 2021, 28, R141-R155.	1.6	16
1152	Recapitulating Tumorigenesis in vitro: Opportunities and Challenges of 3D Bioprinting. Frontiers in Bioengineering and Biotechnology, 2021, 9, 682498.	2.0	16
1153	Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 199-207.	2.0	3
1154	First international workshop of the ATM and cancer risk group (4-5 December 2019). Familial Cancer, 2022, 21, 211-227.	0.9	10
1155	Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer. Mechanisms of Ageing and Development, 2021, 196, 111494.	2.2	4
1156	Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes. Cancers, 2021, 13, 3272.	1.7	14
1157	High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids. SLAS Discovery, 2021, 26, 1107-1124.	1.4	30

#	Article	IF	Citations
1158	ATM-phosphorylated SPOP contributes to 53BP1 exclusion from chromatin during DNA replication. Science Advances, 2021, 7, .	4.7	22
1159	Prostateâ€specific antigen levels of â‰¤4 and >4 ng/mL and risk of prostate cancerâ€specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer. Cancer, 2021, 127, 2222-2228.	2.0	6
1160	Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?. European Urology, 2021, 79, 710-712.	0.9	9
1161	Olaparib for the treatment of metastatic prostate cancer. Future Oncology, 2021, 17, 2413-2429.	1.1	2
1162	Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management. Cancers, 2021, 13, 3556.	1.7	9
1163	Association of germline ATM mutations and survival in pancreatic cancer. Annals of Pancreatic Cancer, 0, 4, 1-1.	1.2	1
1165	Association of intraductal carcinoma of the prostate detected by initial histological specimen and neuroendocrine prostate cancer: A report of three cases. Pathology International, 2021, 71, 621-626.	0.6	1
1166	Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nature Reviews Clinical Oncology, 2021, 18, 773-791.	12.5	198
1167	Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 8.e11-8.e18.	0.8	8
1168	Overview of Olaparib as a treatment option for metastatic castration-resistant prostate cancer. Expert Opinion on Pharmacotherapy, 2021, 22, 1955-1959.	0.9	0
1169	Observed evidence for guidelineâ€recommended genes in predicting prostate cancer risk from a large populationâ€based cohort. Prostate, 2021, 81, 1002-1008.	1.2	10
1170	A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries. Oncology and Therapy, 2021, 9, 311-327.	1.0	1
1171	Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 7884.	1.8	8
1172	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 71-78.	2.0	19
1173	Overexpression of claspin promotes docetaxel resistance and is associated with prostateâ€specific antigen recurrence in prostate cancer. Cancer Medicine, 2021, 10, 5574-5588.	1.3	11
1174	Multi-gene mutation metastatic castrate-resistant prostate cancer. BMJ Case Reports, 2021, 14, e243124.	0.2	1
1175	Genetic Landscape of Male Breast Cancer. Cancers, 2021, 13, 3535.	1.7	22
1176	Genetic Contribution to Metastatic Prostate Cancer. Urologic Clinics of North America, 2021, 48, 349-363.	0.8	0

#	Article	IF	Citations
1177	Radionuclide Therapy in Prostate Cancer: From Standalone to Combination PSMA Theranostics. Journal of Nuclear Medicine, 2021, 62, 1660-1668.	2.8	16
1178	PARP inhibitors in advanced prostate cancer: when to use them?. Endocrine-Related Cancer, 2021, 28, T79-T93.	1.6	5
1179	Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. European Urology, 2021, 80, 243-253.	0.9	28
1180	Prostate Cancer Predisposition. Urologic Clinics of North America, 2021, 48, 283-296.	0.8	12
1181	Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study. Breast Cancer, 2022, 29, 92-102.	1.3	2
1182	Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy. Clinical Genitourinary Cancer, 2022, 20, 97-101.	0.9	14
1183	Germline Testing for Prostate Cancer Prognosis. Urologic Clinics of North America, 2021, 48, 401-409.	0.8	4
1184	Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). JCO Precision Oncology, 2021, 5, 1432-1442.	1.5	29
1185	Clinical Multigene Testing for Prostate Cancer. Urologic Clinics of North America, 2021, 48, 297-309.	0.8	2
1186	Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. Journal of Clinical Oncology, 2021, 39, 2497-2505.	0.8	113
1187	Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer. OncoTargets and Therapy, 2021, Volume 14, 4383-4389.	1.0	3
1188	Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions. Oncotarget, 2021, 12, 1600-1614.	0.8	14
1189	A novel germline BRCA2 mutation in a Chinese patient with prostate cancer sensitive to platinum chemotherapy: a case report. BMC Urology, 2021, 21, 114.	0.6	2
1190	Germline Mutations in African American Men With Prostate Cancer: Incidence, Implications and Diagnostic Disparities. Urology, 2022, 163, 148-155.	0.5	3
1191	Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP. European Urology, 2021, 80, 123-126.	0.9	4
1192	Upregulation of miR-18a-5p promotes the proliferation of prostate cancer via inhibiting the expression of SLC40A1. Pathology Research and Practice, 2021, 224, 153448.	1.0	14
1193	Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches. Frontiers in Oncology, 2021, 11, 732766.	1.3	2
1194	Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?. Pharmacogenomics, 2021, 22, 809-819.	0.6	6

#	Article	IF	Citations
1195	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. European Urology Oncology, 2021, 4, 570-579.	2.6	38
1196	CX-5461 Sensitizes DNA Damage Repairâ€“proficient Castrate-resistant Prostate Cancer to PARP Inhibition. Molecular Cancer Therapeutics, 2021, 20, 2140-2150.	1.9	9
1197	Going beyond Polycomb: EZH2 functions in prostate cancer. Oncogene, 2021, 40, 5788-5798.	2.6	40
1198	Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. Cancer, 2021, 127, 4393-4402.	2.0	24
1199	Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate. BJU International, 2022, 129, 345-355.	1.3	18
1200	Genetically Informed Prostate Cancer Treatment for Metastatic Disease. Urologic Clinics of North America, 2021, 48, 365-371.	0.8	0
1201	Multi-Dimensional Scaling Analysis of Key Regulatory Genes in Prostate Cancer Using the TCGA Database. Genes, 2021, 12, 1350.	1.0	2
1202	Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness. Urologic Clinics of North America, 2021, 48, 339-347.	0.8	5
1203	Genomic Determinants of Homologous Recombination Deficiency across Human Cancers. Cancers, 2021, 13, 4572.	1.7	3
1204	Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives. Cancer Letters, 2021, 523, 162-169.	3.2	24
1205	Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection. OncoTargets and Therapy, 2021, Volume 14, 4819-4832.	1.0	11
1206	Molecular Characterization of Prostate Cancers in the Precision Medicine Era. Cancers, 2021, 13, 4771.	1.7	10
1207	Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?. Anticancer Research, 2021, 41, 4687-4695.	0.5	2
1208	Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). Targeted Oncology, 2021, 16, 613-623.	1.7	6
1209	Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report. World Journal of Clinical Cases, 2021, 9, 7498-7503.	0.3	8
1210	Androgens in prostate cancer: A tale that never ends. Cancer Letters, 2021, 516, 1-12.	3.2	23
1211	Targeted Sequencing Revealed Distinct Mutational Profiles of Ocular and Extraocular Sebaceous Carcinomas. Cancers, 2021, 13, 4810.	1.7	5
1212	PD50-02â€ƒPROSTATE SPECIFIC ANTIGEN DYNAMICS AND PROSTATE CANCER RISK: A POPULATION-BASED STUDY. Journal of Urology, 2021, 206, .	0.2	0

#	Article	IF	Citations
1213	Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. Clinical Cancer Research, 2021, 27, 6106-6114.	3.2	9
1214	Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer. Cancers, 2021, 13, 4522.	1.7	22
1215	Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report. Clinical Lung Cancer, 2021, 22, e703-e707.	1.1	5
1216	Application of Organoid Models in Prostate Cancer Research. Frontiers in Oncology, 2021, 11, 736431.	1.3	11
1217	PARP Inhibitors in Melanomaâ€"An Expanding Therapeutic Option?. Cancers, 2021, 13, 4520.	1.7	8
1218	Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic. International Journal of Molecular Sciences, 2021, 22, 9783.	1.8	35
1219	Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer. European Urology, 2021, 80, 295-303.	0.9	15
1220	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. Journal of the National Cancer Institute, 2022, 114, 271-279.	3.0	27
1221	Talazoparib: a new biomarker-directed therapy in advanced prostate cancer. Lancet Oncology, The, 2021, 22, 1203-1204.	5.1	1
1222	Access and Representation: A Narrative Review of the Disparities in Access to Clinical Trials and Precision Oncology in Black men with Prostate Cancer. Urology, 2022, 163, 90-98.	0.5	6
1223	Prostate cancer. Lancet, The, 2021, 398, 1075-1090.	6.3	240
1224	Synthetic lethality theory approaches to effective substance discovery and functional mechanisms elucidation of anti-cancer phytomedicine. Phytomedicine, 2021, 91, 153718.	2.3	5
1225	Discovering a qualitative transcriptional signature of homologous recombination defectiveness for prostate cancer. IScience, 2021, 24, 103135.	1.9	10
1226	Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. Trends in Cancer, 2021, 7, 958-970.	3.8	18
1227	Dysfunctional activity of classical DNA end-joining renders acquired resistance to carboplatin in human ovarian cancer cells. Cancer Letters, 2021, 520, 267-280.	3.2	7
1228	Asesoramiento genÃ©tico en cÃ¡ncer de prÃ³stata: Â¿cÃ³mo implementarlo en la prÃ¡ctica clÃnica diaria?. Actas UrolÃ³gicas EspaÃ±olas, 2021, 45, 8-20.	0.3	2
1229	Prostate cancer: Therapeutic prospect with herbal medicine. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100034.	1.7	13
1230	Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated (ATM) Gene are Associated with High and Moderate Risks for Multiple Cancers. Cancer Prevention Research, 2021, 14, 433-440.	0.7	68

#	Article	IF	Citations
1231	DNA Damage Response. , 2021, , 1-12.		0
1232	Genetic counseling in prostate cancer: How to implement it in daily clinical practice?. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2021, 45, 8-20.	0.2	1
1233	The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors. Clinical Medicine Insights: Oncology, 2021, 15, 117955492199628.	0.6	33
1234	Genetic Analysis of Circulating Tumour Cells. Recent Results in Cancer Research, 2020, 215, 57-76.	1.8	12
1236	Germline and Somatic Defects in DNA Repair Pathways in Prostate Cancer. Advances in Experimental Medicine and Biology, 2019, 1210, 279-300.	0.8	7
1237	Prostate Cancer Genomic Subtypes. Advances in Experimental Medicine and Biology, 2019, 1210, 87-110.	0.8	8
1238	The Clinical Genomics of Prostate Cancer. , 2017, , 97-110.		2
1239	Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. Critical Reviews in Oncology/Hematology, 2020, 152, 102994.	2.0	13
1240	Identification and quantification of DNA repair protein poly(ADP ribose) polymerase 1 (PARP1) in human tissues and cultured cells by liquid chromatography/isotope-dilution tandem mass spectrometry. DNA Repair, 2019, 75, 48-59.	1.3	4
1241	The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer. Urologic Clinics of North America, 2020, 47, e17-e54.	0.8	39
1243	Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene, 2020, 39, 4869-4883.	2.6	119
1244	Diagnosing hereditary cancer predisposition in men with prostate cancer. Genetics in Medicine, 2020, 22, 1517-1523.	1.1	30
1245	Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity. Nature Communications, 2018, 9, 2419.	5.8	374
1246	Homologous recombination repair deficiency as a therapeutic target in sarcoma. Seminars in Oncology, 2020, 47, 380-389.	0.8	26
1252	Genomics of lethal prostate cancer at diagnosis and castration resistance. Journal of Clinical Investigation, 2020, 130, 1743-1751.	3.9	180
1253	The landscape of RNA polymerase IIâ€“associated chromatin interactions in prostate cancer. Journal of Clinical Investigation, 2020, 130, 3987-4005.	3.9	37
1254	Differential impact of RB status on E2F1 reprogramming in human cancer. Journal of Clinical Investigation, 2017, 128, 341-358.	3.9	83
1255	Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome. JCO Precision Oncology, 2019, 3, 1-12.	1.5	13

#	Article	IF	Citations
1256	Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects. F1000Research, 2018, 7, 1173.	0.8	37
1257	Advances in genetics: widening our understanding of prostate cancer. F1000Research, 2016, 5, 1512.	0.8	2
1258	PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells. PLoS ONE, 2016, 11, e0159341.	1.1	35
1259	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 358-369.	1.8	8
1260	DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC). World Journal of Oncology, 2018, 9, 119-122.	0.6	2
1261	ATM deficiency promotes progression of CRPC by enhancing Warburg effect. Endocrine-Related Cancer, 2019, 26, 59-71.	1.6	19
1262	Caspase-3 knockout attenuates radiation-induced tumor repopulation via impairing the ATM/p53/Cox-2/PGE2 pathway in non-small cell lung cancer. Aging, 2020, 12, 21758-21776.	1.4	16
1263	The role of PTEN as a cancer biomarker. Oncoscience, 2016, 3, 54-55.	0.9	15
1264	Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers. Oncotarget, 2016, 7, 51965-51980.	0.8	35
1265	Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget, 2016, 7, 64447-64470.	0.8	130
1266	BRIP1coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease. Oncotarget, 2017, 8, 62842-62857.	0.8	7
1267	Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer. Oncotarget, 2016, 7, 62240-62254.	0.8	23
1268	Germline mutations in Japanese familial pancreatic cancer patients. Oncotarget, 2016, 7, 74227-74235.	0.8	62
1269	The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?. Oncotarget, 2017, 8, 1957-1971.	0.8	38
1270	Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM. Oncotarget, 2017, 8, 10312-10323.	0.8	31
1271	â€œBack to a false normalityâ€• new intriguing mechanisms of resistance to PARP inhibitors. Oncotarget, 2017, 8, 23891-23904.	0.8	24
1272	Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. Oncotarget, 2017, 8, 22218-22234.	0.8	46
1273	The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells. Oncotarget, 2017, 8, 31815-31829.	0.8	51

#	Article	IF	Citations
1274	BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer. Oncotarget, 2017, 8, 40222-40232.	0.8	18
1275	IER5 as a promising predictive marker promotes irradiation-induced apoptosis in cervical cancer tissues from patients undergoing chemoradiotherapy. Oncotarget, 2017, 8, 36438-36448.	0.8	8
1276	Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget, 2017, 8, 47154-47160.	0.8	23
1277	Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget, 2017, 8, 44073-44081.	0.8	63
1278	DNA repair deregulation in discrete prostate cancer lesions identified on multi-parametric MRI and targeted by MRI/ultrasound fusion-guided biopsy. Oncotarget, 2017, 8, 68038-68046.	0.8	4
1279	Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer. Oncotarget, 2017, 8, 77181-77194.	0.8	25
1280	The miR-486-5p plays a causative role in prostate cancer through negative regulation of multiple tumor suppressor pathways. Oncotarget, 2017, 8, 72835-72846.	0.8	51
1281	Increased single-strand annealing rather than non-homologous end-joining predicts hereditary ovarian carcinoma. Oncotarget, 2017, 8, 98660-98676.	0.8	7
1282	Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness. Oncotarget, 2017, 8, 93315-93316.	0.8	8
1283	High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. Oncotarget, 2017, 8, 104430-104443.	0.8	5
1284	Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma. Oncotarget, 2018, 9, 18198-18213.	0.8	37
1285	Genomic loss of heterozygosity and survival in the REAL3 trial. Oncotarget, 2018, 9, 36654-36665.	0.8	13
1286	Computational analysis of data from a genome-wide screening identifies new PARP1 functional interactors as potential therapeutic targets. Oncotarget, 2019, 10, 2722-2737.	0.8	11
1287	Inherited DNA-repair gene mutations in African American men with prostate cancer. Oncotarget, 2020, 11, 440-442.	0.8	18
1288	Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line. Oncotarget, 2020, 11, 1653-1665.	0.8	4
1289	Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors. Oncotarget, 2016, 7, 7701-7714.	0.8	35
1290	Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology. , 2019, 2, 608-617.		3
1291	Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways. , 2020, 3, 726-741.		6

#	Article	IF	Citations
1292	Current status of circulating tumor cell androgen receptor splice variant-7 in metastatic castration-resistant prostate cancer. Annals of Translational Medicine, 2019, 7, S375-S375.	0.7	2
1293	Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Current Medicinal Chemistry, 2017, 24, 1586-1606.	1.2	89
1294	DNA Double Strand Break Repair - Related Synthetic Lethality. Current Medicinal Chemistry, 2019, 26, 1446-1482.	1.2	9
1295	Molecular basis of inherited colorectal carcinomas in the Macedonian population: An update. Balkan Journal of Medical Genetics, 2019, 22, 5-16.	0.5	1
1296	PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation. Cancers, 2020, 12, 394.	1.7	91
1297	The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis. Cancers, 2020, 12, 1178.	1.7	10
1298	Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein. World Journal of Gastroenterology, 2016, 22, 10680.	1.4	15
1299	The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer. Asian Journal of Andrology, 2016, 18, 592.	0.8	2
1300	Long noncoding RNAs in prostate cancer: overview and clinical implications. Asian Journal of Andrology, 2016, 18, 568.	0.8	41
1301	Personalized prostate cancer care: from screening to treatment. Asian Journal of Andrology, 2016, 18, 505.	0.8	8
1302	Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer. Asian Journal of Andrology, 2019, 21, 270.	0.8	15
1303	The path forward in prostate cancer therapeutics. Asian Journal of Andrology, 2018, 20, 213.	0.8	3
1304	Perspectives on the clinical development of immunotherapy in prostate cancer. Asian Journal of Andrology, 2018, 20, 253.	0.8	13
1305	The hallmarks of cancer and their therapeutic targeting in current use and clinical trials. Iraqi Journal of Hematology, 2020, 9, 1.	0.0	6
1306	Circulating Tumour DNA as a Biomarker Source in Metastatic Prostate Cancer. SociÃ©tÃ© Internationale D'urologie Journal, 2020, 1, 39-48.	0.2	3
1307	A Urologistâ€™s Personal View of Prostate Cancer. Turkish Journal of Urology, 2016, 42, 121-126.	1.3	7
1308	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 479-505.	2.3	943
1309	Germline and Somatic Mutations in Prostate Cancer for the Clinician. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 515-521.	2.3	91

#	Article	IF	Citations
1310	Blockade of the LRP16-PKR-NF-Î²B signaling axis sensitizes colorectal carcinoma cells to DNA-damaging cytotoxic therapy. ELife, 2017, 6, .	2.8	19
1311	Rev7 and 53BP1/Crb2 prevent RecQ helicase-dependent hyper-resection of DNA double-strand breaks. ELife, 2018, 7, .	2.8	21
1312	AR phosphorylation and CHK2 kinase activity regulates IR-stabilized ARâ€“CHK2 interaction and prostate cancer survival. ELife, 2020, 9, .	2.8	4
1313	Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer. Cureus, 2019, 11, e5197.	0.2	4
1314	Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study. In Vivo, 2021, 35, 3509-3519.	0.6	5
1315	How I faced my prostate cancer: a molecular biologistâ€™s perspective. Npj Precision Oncology, 2021, 5, 88.	2.3	1
1316	First successful case of platinumâ€based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations. IJU Case Reports, 2022, 5, 41-44.	0.1	3
1317	Genetics in prostate cancer: implications for clinical practice. Current Opinion in Supportive and Palliative Care, 2021, 15, 241-246.	0.5	4
1318	Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk. Current Genetic Medicine Reports, 2021, 9, 47-58.	1.9	5
1319	Prostate zones and cancer: lost in transition?. Nature Reviews Urology, 2022, 19, 101-115.	1.9	25
1320	PARP inhibitors: clinical relevance and the role of multidisciplinary cancer teams on drug safety. Expert Opinion on Drug Safety, 2022, 21, 541-551.	1.0	2
1321	DNA Damage. , 2014, , 1382-1387.		0
1322	DNA Damage. , 2014, , 1-7.		0
1323	Emerging Therapeutic Targets in Pancreatic Adenocarcinoma. , 2016, , 1-29.		1
1324	Pancreatic cancer: molecular genomics and clinical applications. Suizo, 2016, 31, 10-16.	0.1	0
1325	Neuroendocrine and Small Cell Carcinomas of the Prostate: Sentinels of Lethal Evolution. , 2016, , 191-204.		0
1326	The Emerging Role of PARP Inhibitors in the Treatment of Prostate Cancer. , 0, , .		0
1328	Chemotherapy and Androgen Receptor-Directed Treatment of Castration Resistant Metastatic Prostate Cancer. , 2017, , 327-342.		0

#	Article	IF	Citations
1329	DNA Damage. , 2017, , 1-7.		0
1330	Synthetic Lethality: Achilles Heel in Select Patient Subpopulations. , 2018, , 257-270.		0
1332	DNA Mismatch Repair in Advanced Metastatic Prostate Carcinoma: Clinical Perspective. Journal of Cancer Prevention & Current Research, 2017, 8, .	0.1	0
1333	Applying precision medicine approach to metastatic castration-resistant prostate cancer: urgent education need on genomic oncology. , 2018, 02, .		0
1334	Evaluation and Treatment for High-Risk Prostate Cancer. , 2018, , 135-156.		0
1336	Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. , 2018, , 1-14.		0
1337	Should we Address Biochemical Recurrence of Prostate Cancer as Soon as Possible? Against. European Oncology and Haematology, 2018, 14, 14.	0.0	0
1338	New Targeted Approach to CRPC. , 2018, , 375-385.		0
1343	Molecular Pathology of Genitourinary Cancers: Translating the Cancer Genome to theÂClinic. , 2019, , 419-443.		0
1344	Precision Medicine in Castration-Resistant Prostate Cancer. The Korean Journal of Urological Oncology, 2018, 16, 97-102.	0.1	0
1345	Genomic analysis of Korean patients with advanced prostate cancer by use of a comprehensive next-generation sequencing panel and low-coverage, whole-genome sequencing. Investigative and Clinical Urology, 2019, 60, 227.	1.0	4
1346	Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. , 2019, , 241-253.		0
1348	Evolving Role of Genomics in Genitourinary Neoplasms. Acta Medica Academica, 2019, 48, 68.	0.3	2
1349	Better screened than sorry!â€"an informed panel of inherited DNA repair gene variants for prostate cancer screening and prognostication. Annals of Translational Medicine, 2019, 7, S158-S158.	0.7	0
1351	Multi-omics analysis reveals the BRCA1 mutation and mismatch repair gene signatures associated with survival, protein expression, and copy number alterations in prostate cancer. Translational Cancer Research, 2019, 8, 1279-1288.	0.4	1
1352	Current topics in hereditary breast and ovarian cancer. Okayama Igakkai Zasshi, 2019, 131, 89-96.	0.0	1
1354	Expression Profiles of IGF1, EGF, and FGF2 Genes in Patients With Prostate Cancer in Isfahan Province, Iran. Research in Molecular Medicine, 0, , 39-44.	0.1	0
1357	Study on Big Data-Supported Clinical Oncology. , 2020, , 325-349.		0

#	Article	IF	Citations
1358	Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time. Healthbook TIMES Oncology Hematology, 2019, , 10-17.	0.1	1
1359	Recent Advances in DNA Repair Pathway and Its Application in Personalized Care of Metastatic Castration-Resistant Prostate Cancer (mCRPC). Methods in Molecular Biology, 2020, 2204, 75-89.	0.4	2
1360	Integrating Germline Genetics Into Precision Oncology Practice in the Veterans Health Administration: Challenges and Opportunities. , 2020, 37, S82-S88.		4
1361	Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer. Oncology Letters, 2020, 20, 1-1.	0.8	0
1362	Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. Nature Communications, 2021, 12, 6248.	5.8	15
1363	Identification of DNA Damage Repair-Associated Prognostic Biomarkers for Prostate Cancer Using Transcriptomic Data Analysis. International Journal of Molecular Sciences, 2021, 22, 11771.	1.8	6
1364	Olaparib: Transcending mutational barriers. Indian Journal of Urology, 2020, 35, 85.	0.2	0
1365	Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort. PLoS ONE, 2020, 15, e0244149.	1.1	4
1366	Attenuation of SRC Kinase Activity Augments PARP Inhibitorâ€“mediated Synthetic Lethality in BRCA2-altered Prostate Tumors. Clinical Cancer Research, 2021, 27, 1792-1806.	3.2	13
1367	Anticipating the Next Challenging Clinical Dilemmas in Prostate Cancer. JCO Oncology Practice, 2020, 16, 791-792.	1.4	0
1368	Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 68-73.	0.6	5
1369	Abiraterone acetate plus prednisone/prednisolone in hormone-sensitive and castration-resistant metastatic prostate cancer. Expert Review of Precision Medicine and Drug Development, 2021, 6, 41-49.	0.4	1
1370	Molekularpathologie und Biomarker. , 2020, , 173-183.		0
1371	Chemotherapeutic Agents for Urologic Oncology: Basic Principles. , 2020, , 611-637.		0
1372	Hereditary Breast and Ovarian Cancer Syndrome (BRCA) Gene: Concept, Pathways, Therapeutics, and Future. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 9-14.	0.1	0
1374	Targeted therapy with Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of solid tumours. Journal of Education, Health and Sport, 2020, 10, 133.	0.0	0
1375	Next-Generation Sequencing in Prostate Cancer. The Korean Journal of Urological Oncology, 2020, 18, 18-23.	0.1	0
1376	Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology. Pharmacogenomics, 2021, 22, 1237-1250.	0.6	1

#	Article	IF	Citations
1378	PREVENTING THE CHROMOSOMAL TRANSLOCATIONS THAT CAUSE CANCER. Transactions of the American Clinical and Climatological Association, 2016, 127, 176-195.	0.9	7
1379	THE GORDON WILSON LECTURE EVOLUTION OF CLINICAL CANCER GENETICS. Transactions of the American Clinical and Climatological Association, 2016, 127, 127-139.	0.9	1
1380	Inherited Predisposition to Prostate Cancer: From Gene Discovery to Clinical Impact. Transactions of the American Clinical and Climatological Association, 2017, 128, 14-23.	0.9	11
1381	CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer. American Journal of Cancer Research, 2020, 10, 1140-1155.	1.4	9
1382	The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target. American Journal of Clinical and Experimental Urology, 2021, 9, 73-87.	0.4	4
1383	Genetic Mutations Associated With Prostate Cancer and Normal Serum PSA and DRE-Implications for Prostate Cancer Screening and Management: NYU Case of the Month, November 2020. Reviews in Urology, 2020, 22, 177-181.	0.9	0
1384	Niclosamide exerts anticancer effects through inhibition of the FOXM1-mediated DNA damage response in prostate cancer. American Journal of Cancer Research, 2021, 11, 2944-2959.	1.4	1
1386	Genetics of prostate cancer and its utility in treatment and screening. Advances in Genetics, 2021, 108, 147-199.	0.8	3
1387	Epigenetics and precision medicine in prostate cancer. , 2022, , 69-108.		0
1389	Overall and progressionâ€free survival of Afroâ€Caribbean men with metastatic castrationâ€resistant prostate cancer (mCRPC). Prostate, 2022, 82, 269-275.	1.2	3
1390	BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations. International Journal of Molecular Sciences, 2021, 22, 12628.	1.8	44
1391	Germinal <i>BRCA</i>-mutation significance in the tumor microenvironment formation Efficacy of PARP inhibition in late-line therapy of metastatic castration-resistant prostate cancer. Onkourologiya, 2021, 17, 85-94.	0.1	2
1392	Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients. Cells, 2021, 10, 3223.	1.8	4
1393	HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Research, 2021, 81, 6207-6218.	0.4	25
1394	Analysis of Mutations and Dysregulated Pathways Unravels Carcinogenic Effect and Clinical Actionability of Mutational Processes. Frontiers in Cell and Developmental Biology, 2021, 9, 768981.	1.8	1
1395	MET inhibition enhances PARP inhibitor efficacy in castrationâ€resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways. Journal of Cellular and Molecular Medicine, 2021, 25, 11157-11169.	1.6	14
1396	Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study. Annals of Translational Medicine, 2021, 9, 1661-1661.	0.7	11
1397	DNA Damage Response. , 2021, , 536-547.		0

#	Article	IF	Citations
1398	Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance. , 2021, 4, 984-995.		1
1400	Biomarker-driven immunotherapy for precision medicine in prostate cancer. Personalized Medicine, 2022, 19, 51-66.	0.8	1
1401	Genetic Analysis Reveals the Prognostic Significance of the DNA Mismatch Repair Gene MSH2 in Advanced Prostate Cancer. Cancers, 2022, 14, 223.	1.7	5
1402	Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nature Medicine, 2022, 28, 144-153.	15.2	102
1403	Hormonal Therapy for Prostate Cancer. , 2022, , 1790-1804.		0
1404	Analysis of Machine Learning Techniques for Detection Framework for DNA Repair Genes to help Diagnose Cancer: A Systematic Literature Review. , 2021, , .		1
1405	PARP Inhibitors in Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2021, 27, 465-475.	1.0	18
1406	An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. International Journal of Molecular Sciences, 2021, 22, 13519.	1.8	13
1407	Poly (ADP-ribose) polymerase 1 (PARP1) inhibition promotes pulmonary metastasis of osteosarcoma by boosting ezrin phosphorylation. International Journal of Biological Sciences, 2022, 18, 1238-1253.	2.6	3
1408	Prostate cancer immunotherapy. Expert Opinion on Biological Therapy, 2022, 22, 577-590.	1.4	17
1409	Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing. Annals of Oncology, 2022, 33, 426-433.	0.6	18
1410	PROFOUND trial â€“a new era in targeted therapeutics for prostate carcinoma. Indian Journal of Urology, 2022, 38, 73.	0.2	1
1411	Olaparib-Induced Senescence Is Bypassed through G2â€“M Checkpoint Override in Olaparib-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2022, 21, 677-685.	1.9	6
1412	Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets. Cancers, 2022, 14, 664.	1.7	7
1413	Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy. JNCI Cancer Spectrum, 2022, 6, pkac001.	1.4	3
1415	Identification and Characterization of an Exonic Duplication in PALB2 in a Man with Synchronous Breast and Prostate Cancer. International Journal of Molecular Sciences, 2022, 23, 667.	1.8	2
1416	<scp>PARP</scp> mediated <scp>DNA</scp> damage response, genomic stability and immune responses. International Journal of Cancer, 2022, 150, 1745-1759.	2.3	18
1417	Rational Second-Generation Antiandrogen Use in Prostate Cancer. Oncologist, 0, , .	1.9	10

#	Article	IF	Citations
1418	DNA damage response inhibitor and anti-PD-L1 therapy for prostate cancer: Development of predictive biomarkers. Engineering, 2022, , .	3.2	0
1419	DNAâ€repair status should be assessed in treatmentâ€emergent neuroendocrine prostate cancer before platinumâ€based therapy. Prostate, 2022, 82, 464-474.	1.2	2
1420	Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). Clinical Cancer Research, 2022, 28, 1518-1530.	3.2	41
1421	Hereditary Cancer Gene Variants in Hispanic Men With a Personal or Family History of Prostate Cancer. Clinical Genitourinary Cancer, 2022, 20, 237-243.	0.9	2
1422	Platinum-Based Neoadjuvant Chemotherapy Before Radical Prostatectomy for Locally Advanced Prostate Cancer With Homologous Recombination Deficiency: A Case Report. Frontiers in Oncology, 2021, 11, 777318.	1.3	2
1423	Implementation of a prostate cancerâ€specific targeted sequencing panel for credentialing of patientâ€derived cell lines and genomic characterization of patient samples. Prostate, 2022, , .	1.2	1
1424	ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. Journal of the National Cancer Institute, 2022, 114, 761-770.	3.0	3
1425	Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics. Cancer Letters, 2022, 531, 71-82.	3.2	17
1426	BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2022, 40, 345-355.	0.8	23
1427	Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology. Cancer Treatment Reviews, 2022, 104, 102337.	3.4	6
1428	Cyclin D1 Binding Protein 1 Responds to DNA Damage through the ATMâ€“CHK2 Pathway. Journal of Clinical Medicine, 2022, 11, 851.	1.0	2
1430	Angiogenesis as Therapeutic Target in Metastatic Prostate Cancer â€“ Narrowing the Gap Between Bench and Bedside. Frontiers in Immunology, 2022, 13, 842038.	2.2	7
1431	Intraductal Carcinoma of the Prostate as a Cause of Prostate Cancer Metastasis: A Molecular Portrait. Cancers, 2022, 14, 820.	1.7	13
1433	PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence. Cancer Treatment Reviews, 2022, 104, 102359.	3.4	9
1434	PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components. OncoTargets and Therapy, 2022, Volume 15, 165-180.	1.0	15
1435	RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?. Expert Review of Molecular Diagnostics, 2022, 22, 185-199.	1.5	16
1436	The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation. Asian Journal of Urology, 2022, 9, 480-482.	0.5	2
1437	PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: Whatâ€™s Now, Whatâ€™s New, and Whatâ€™s Coming?. Cancers, 2022, 14, 907.	1.7	8

#	Article	IF	Citations
1438	Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets. Clinical Genitourinary Cancer, 2022, , .	0.9	1
1439	Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition. Cancers, 2022, 14, 897.	1.7	13
1440	Implications of DNA damage repair alterations for the management of prostate cancer. Current Opinion in Urology, 2022, 32, 302-310.	0.9	1
1441	Inhibitors of PARP: Number crunching and structure gazing. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2121979119.	3.3	52
1442	Application of Regulatory Cell Death in Cancer: Based on Targeted Therapy and Immunotherapy. Frontiers in Immunology, 2022, 13, 837293.	2.2	23
1443	GIPC2 interacts with Fzd7 to promote prostate cancer metastasis by activating WNT signaling. Oncogene, 2022, 41, 2609-2623.	2.6	13
1444	Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy. International Journal of Molecular Sciences, 2022, 23, 3238.	1.8	14
1445	Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer. Cancers, 2022, 14, 1388.	1.7	22
1446	Hereditary cancer risk assessment and genetic testing in the community urology practice setting. Prostate, 2022, , .	1.2	0
1447	Germline Pathogenic Variants in BRCA1 and BRCA2: Malignancies Beyond Female Breast and Ovarian Cancers. Journal of Clinical Oncology, 2022, , JCO2200003.	0.8	0
1448	Pre-activation of autophagy impacts response to olaparib in prostate cancer cells. Communications Biology, 2022, 5, 251.	2.0	6
1449	Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes. Nature Communications, 2022, 13, 1361.	5.8	8
1450	Targeting radioresistance and replication fork stability in prostate cancer. JCI Insight, 2022, 7, .	2.3	4
1451	The role of genetic testing in prostate cancer screening, diagnosis, and treatment. Current Opinion in Oncology, 2022, Publish Ahead of Print, .	1.1	0
1452	Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer. Current Oncology, 2022, 29, 1902-1918.	0.9	5
1453	FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing. Journal of Clinical Pathology, 2023, 76, 548-554.	1.0	1
1454	PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers. Journal of Clinical Medicine, 2022, 11, 1734.	1.0	5
1455	PARP Inhibitors Resistance: Mechanisms and Perspectives. Cancers, 2022, 14, 1420.	1.7	22

#	Article	IF	Citations
1456	Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation. Journal of Oncology Pharmacy Practice, 2023, 29, 1094-1102.	0.5	4
1457	SEOM-GETTHI clinical guideline for the practical management of molecular platforms (2021). Clinical and Translational Oncology, 2022, 24, 693-702.	1.2	1
1458	Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report. World Journal of Clinical Cases, 2022, 10, 3461-3471.	0.3	2
1459	Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitorâ€"resistant cancer. Pharmacological Research, 2022, 178, 106162.	3.1	40
1460	Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors. Cancer Journal (Sudbury, Mass), 2021, 27, 482-490.	1.0	0
1461	PARP Inhibition in Advanced Prostate Cancer. Cancer Journal (Sudbury, Mass), 2021, 27, 457-464.	1.0	3
1462	Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. Clinical Breast Cancer, 2021, , .	1.1	6
1463	Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer. JCI Insight, 2021, 6, .	2.3	15
1464	PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. Cancers, 2021, 13, 6385.	1.7	19
1465	Clinical and biological relevance of the transcriptomicâ€based prostate cancer metastasis subtypes MetAâ€C. Molecular Oncology, 2022, 16, 846-859.	2.1	8
1466	Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer. Cancers, 2022, 14, 51.	1.7	12
1467	Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 777663.	1.6	12
1468	Race-Specific Genetic Profiles of Homologous Recombination Deficiency in Multiple Cancers. Journal of Personalized Medicine, 2021, 11, 1287.	1.1	5
1469	Dysregulation of DNA Methylation and Epigenetic Clocks in Prostate Cancer among Puerto Rican Men. Biomolecules, 2022, 12, 2.	1.8	1
1470	Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer. Pharmaceuticals, 2021, 14, 1270.	1.7	5
1471	Identification of molecular subtypes and prognostic signature for hepatocellular carcinoma based on genes associated with homologous recombination deficiency. Scientific Reports, 2021, 11, 24022.	1.6	5
1472	Prognostic Value of an Immune-Related Gene Signature in Oral Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 776979.	1.3	2
1473	Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate. International Journal of Molecular Sciences, 2021, 22, 13125.	1.8	6

#	Article	IF	Citations
1474	Case Report: Olaparib Shows Satisfactory Clinical Outcomes Against Small Cell Esophageal Carcinoma With ATM Mutation. Frontiers in Oncology, 2022, 12, 808801.	1.3	0
1475	Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer According to Somatic Damage DNA Repair Gene Alterations. Current Oncology, 2022, 29, 2776-2791.	0.9	3
1476	Rucaparib and olaparib for the treatment of prostate cancer: A clinician's guide to choice of therapy. Journal of Oncology Pharmacy Practice, 2022, 28, 1624-1633.	0.5	4
1477	Germline testing and genetic counselling in prostate cancer. Nature Reviews Urology, 2022, 19, 331-343.	1.9	18
1478	Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials. Pharmaceutics, 2022, 14, 866.	2.0	17
1480	The emerging role of cross-resistance between taxanes and AR-targeting therapy in metastatic prostate cancer. Journal of Clinical Urology, 2024, 17, 182-189.	0.1	0
1487	Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas. Npj Precision Oncology, 2022, 6, 29.	2.3	6
1488	RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer. Science Advances, 2022, 8, eabl9794.	4.7	14
1489	Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitorâ€“Induced Synthetic Lethality. Cancer Research, 2022, 82, 2156-2170.	0.4	23
1490	Exploiting induced vulnerability to overcome PARPi resistance and clonal heterogeneity in BRCA mutant triple-negative inflammatory breast cancer.. American Journal of Cancer Research, 2022, 12, 337-354.	1.4	0
1492	Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients. International Journal of Molecular Sciences, 2022, 23, 4709.	1.8	13
1493	Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors. JCO Precision Oncology, 2022, 6, e2100461.	1.5	2
1494	PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer. Drugs, 2022, 82, 719-733.	4.9	10
1495	Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors. Molecular Cancer Therapeutics, 2022, 21, 1115-1124.	1.9	3
1496	Incidence of grade 3â€“4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 235-240.	1.5	6
1497	Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer. European Urology Oncology, 2022, 5, 659-667.	2.6	8
1498	Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies. Endocrine Reviews, 2022, 43, 1051-1073.	8.9	9
1500	Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer. Current Oncology Reports, 2022, 24, 1287-1298.	1.8	4

#	Article	IF	Citations
1501	Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines. JAMA Network Open, 2022, 5, e2213070.	2.8	21
1502	First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors. Cancer, 2022, , .	2.0	6
1503	Diagnosis and treatment of metastatic prostate cancer. , 2022, , 23-47.		0
1504	The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management. Expert Review of Anticancer Therapy, 0, , 1-9.	1.1	1
1505	Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer. International Journal of Biochemistry and Cell Biology, 2022, 147, 106230.	1.2	2
1506	Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model. Pancreatology, 2022, 22, 760-769.	0.5	1
1507	Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing. European Journal of Case Reports in Internal Medicine, 0, , .	0.2	2
1508	Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis. Medical Oncology, 2022, 39, .	1.2	4
1509	Another Step Towards the Acceptance of Metastasis-directed Therapy in Low-volume Metastatic Prostate Cancer. European Urology Oncology, 2022, , .	2.6	0
1510	Clinical implications of homologous recombination repair mutations in prostate cancer. Prostate, 2022, 82, .	1.2	4
1511	Germline genetics of prostate cancer. Prostate, 2022, 82, .	1.2	8
1513	The impact of genetic aberrations on response to radiumâ€223 treatment for castrationâ€resistant prostate cancer with bone metastases. Prostate, 2022, 82, 1202-1209.	1.2	4
1514	Genomic biomarkers to guide precision radiotherapy in prostate cancer. Prostate, 2022, 82, .	1.2	3
1516	Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 667-90.	0.9	8
1517	Metastasis Model to Test the Role of Notch Signaling in Prostate Cancer. Methods in Molecular Biology, 2022, , 221-233.	0.4	1
1519	A Germline Mutation in ATR Is Associated With Lung Adenocarcinoma in Asian Patients. Frontiers in Oncology, 0, 12, .	1.3	0
1520	Reduced DNA Repair Capacity in Prostate Cancer Patients: A Phenotypic Approach Using the CometChip. Cancers, 2022, 14, 3117.	1.7	2
1521	PARP Inhibitors: A New Horizon for Patients with Prostate Cancer. Biomedicines, 2022, 10, 1416.	1.4	20

#	Article	IF	Citations
1522	Poly (ADP-ribose) polymerase inhibitors (PARPi) for advanced malignancies with multiple DNA-repair genetic aberrations. Expert Review of Anticancer Therapy, 2022, 22, 717-723.	1.1	1
1523	Robust prognostic model based on immune infiltrationâ€related genes and clinical information in ovarian cancer. Journal of Cellular and Molecular Medicine, 0, , .	1.6	1
1524	A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report. BMC Medical Genomics, 2022, 15, .	0.7	1
1525	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	40
1526	The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. Cancers, 2022, 14, 2950.	1.7	9
1527	Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. Breast, 2022, 65, 32-40.	0.9	25
1528	Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies. Current Hematologic Malignancy Reports, 2022, 17, 94-104.	1.2	14
1529	A tale of two alleles: TP53 and transformation in MPNs. Blood, 2022, 139, 3567-3568.	0.6	1
1530	Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. European Journal of Cancer, 2022, 171, 232-241.	1.3	7
1531	Activating STING1-dependent immune signaling inTP53mutant and wild-type acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	9
1532	The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer. Clinical Genitourinary Cancer, 2022, 20, 515-523.	0.9	4
1533	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of Oncology, 2022, 33, 750-768.	0.6	204
1534	Multisite Radiotherapy Combined With Tislelizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label, Single-Arm, Phase Ib/II Study. Frontiers in Oncology, 0, 12, .	1.3	1
1535	Downregulation of PGM5 expression correlates with tumor progression and poor prognosis in human prostate cancer. Discover Oncology, 2022, 13, .	0.8	1
1536	Review of Toxicities of PARP Inhibitors in Metastatic Castrate Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2023, 21, 183-193.	0.9	6
1537	Emerging Biomarker-Guided Therapies in Prostate Cancer. Current Oncology, 2022, 29, 5054-5076.	0.9	10
1538	Unravelling genetic variants of a swedish family with high risk of prostate cancer. Hereditary Cancer in Clinical Practice, 2022, 20, .	0.6	1
1539	PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib. Scientific Reports, 2022, 12, .	1.6	3

#	Article	IF	Citations
1540	Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer. International Journal of Cancer, 2023, 152, 945-951.	2.3	4
1541	PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications. Biomedicine and Pharmacotherapy, 2022, 153, 113458.	2.5	5
1542	IKKÎµ Inhibitor Amlexanox Promotes Olaparib Sensitivity through the C/EBP-Î²-Mediated Transcription of Rad51 in Castrate-Resistant Prostate Cancer. Cancers, 2022, 14, 3684.	1.7	1
1543	Clinical utility of histopathology data: urological cancers. Journal of Clinical Pathology, 2022, 75, 506-513.	1.0	0
1544	Two Cocrystals of Olaparib with Flavonoids toward Sustained Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis. Crystal Growth and Design, 2022, 22, 4885-4894.	1.4	10
1545	Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic. American Journal of Men's Health, 2022, 16, 155798832211155.	0.7	1
1546	Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance. Cancers, 2022, 14, 3877.	1.7	3
1547	A patient-driven clinicogenomic partnership for metastatic prostate cancer. Cell Genomics, 2022, 2, 100169.	3.0	4
1548	Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer. Current Oncology Reports, 0, , .	1.8	4
1549	Motivation and family communication in hereditary prostate cancer genetic testing: Survey of patients from a <scp>US</scp> tertiary medical center. Journal of Genetic Counseling, 0, , .	0.9	1
1550	Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease. Biomedicines, 2022, 10, 1872.	1.4	6
1551	Prostate cancer recurring as smallâ€cell carcinoma with a <scp> BRCA2 </scp> somatic mutation. IJU Case Reports, 0, , .	0.1	0
1552	The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems. Pharmaceutics, 2022, 14, 1647.	2.0	4
1554	Protein Regulator of Cytokinesis 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma. Journal of Immunology Research, 2022, 2022, 1-27.	0.9	1
1555	Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity. Nature Communications, 2022, 13, .	5.8	22
1556	BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. Cancers, 2022, 14, 3888.	1.7	56
1557	Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinicianâ€™s Perspective. Cancer Management and Research, 0, Volume 14, 2389-2397.	0.9	0
1560	DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies. European Surgical Research, 2022, 63, 155-164.	0.6	8

#	Article	IF	Citations
1561	Should We â€œPROpelâ€•Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer?. , 2022, 1, .		0
1563	Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine, 2022, 52, 101595.	3.2	14
1564	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1-55.		0
1565	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1023-1075.		0
1566	The Effect of Prostate Cancer-Targeting Doxorubicin Nanomicelles Combined with Photothermal Therapy on Castration-Resistant Prostate Cancer. Journal of Biomedical Nanotechnology, 2022, 18, 1276-1288.	0.5	1
1567	Bench to bedside: research influencing clinical practice in prostate pathology. Diagnostic Histopathology, 2022, 28, 488-492.	0.2	0
1568	Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. JCO Precision Oncology, 2022, , .	1.5	2
1569	DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination. Frontiers in Oncology, 0, 12, .	1.3	6
1570	Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. Clinical Cancer Research, 2023, 29, 81-91.	3.2	19
1571	Targeted Approaches in Metastatic Castration-Resistant Prostate Cancer: Which Data?. Cancers, 2022, 14, 4189.	1.7	4
1572	Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study. European Urology, 2023, 83, 15-26.	0.9	22
1573	PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures. Cancers, 2022, 14, 4751.	1.7	4
1574	Homeostases of epidermis and hair follicle, and development of basal cell carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188795.	3.3	5
1575	Androgen Receptor Splice Variants Contribute to the Upregulation of DNA Repair in Prostate Cancer. Cancers, 2022, 14, 4441.	1.7	4
1576	Whole-exome sequencing reveals a comprehensive germline mutation landscape and identifies twelve novel predisposition genes in Chinese prostate cancer patients. PLoS Genetics, 2022, 18, e1010373.	1.5	4
1577	Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report. Medicine (United States), 2022, 101, e30719.	0.4	5
1578	B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. European Urology, 2023, 83, 224-238.	0.9	18
1579	Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board. Cancers, 2022, 14, 4430.	1.7	7

#	Article	IF	Citations
1580	Combined BRCA2 and MAGEC3 Expression Predict Outcome in Advanced Ovarian Cancers. Cancers, 2022, 14, 4724.	1.7	0
1581	Metastatic prostate cancer gets into the biomarker era. Canadian Urological Association Journal, 2022, 16, 333.	0.3	0
1582	KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45Î± Pathway. Frontiers in Oncology, 0, 12, .	1.3	1
1583	PARP inhibitors in metastatic prostate cancer: When, who, and how?. International Journal of Molecular and Immuno Oncology, 0, 7, 82-97.	0.0	0
1584	The Value of Phenotypic Precision Medicine in Prostate Cancer. Oncologist, 2023, 28, 93-104.	1.9	5
1585	Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. Frontiers in Endocrinology, 0, 13, .	1.5	7
1586	Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients. Cancer Control, 2022, 29, 107327482211294.	0.7	28
1587	Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer. Biomolecules, 2022, 12, 1590.	1.8	6
1588	Radiotherapy-Related Gene Signature in Prostate Cancer. Cancers, 2022, 14, 5032.	1.7	3
1589	Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology. JCO Precision Oncology, 2022, , .	1.5	7
1590	Following the Narrow Path. European Urology, 2022, , .	0.9	0
1591	Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. Journal of Clinical Oncology, 2023, 41, 871-880.	0.8	15
1592	Ad hocAnalysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in GermlineBRCAWild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects. Cancer Research Communications, 2022, 2, 1436-1444.	0.7	2
1593	What is the most effective way to ensure that patients successfully undergo germline testing for prostate cancer?. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	0
1594	Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter. International Journal of Molecular Sciences, 2022, 23, 12647.	1.8	2
1595	A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nature Cancer, 2022, 3, 1181-1191.	5.7	42
1596	The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nature Communications, 2022, 13, .	5.8	15
1597	The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations. Expert Review of Clinical Pharmacology, 2022, 15, 1293-1304.	1.3	0

#	Article	IF	Citations
1598	Caracteristicas clÃnicas de pacientes con cÃ¡ncer de prÃ³stata resistentes a la castraciÃ³n y alteraciones en genes de reparaciÃ³n por recombinaciÃ³n homÃ³loga. , 2022, 24, .		0
1599	Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation. Frontiers in Oncology, 0, 12, .	1.3	6
1600	Emerging Role of YAP and the Hippo Pathway in Prostate Cancer. Biomedicines, 2022, 10, 2834.	1.4	3
1601	Cell-Free DNA Sequencing Reveals Gene Variants in DNA Damage Repair Genes Associated with Prognosis of Prostate Cancer Patients. Cells, 2022, 11, 3618.	1.8	1
1602	French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance. Progres En Urologie, 2022, 32, 1373-1419.	0.3	5
1603	Differential responses to taxanes and PARP inhibitors in ATMâ€Âversus BRCA2â€mutated metastatic castrateâ€resistant prostate cancer. Prostate, 2023, 83, 227-236.	1.2	5
1604	Metastatic castrate-resistant prostate cancer: a new horizon beyond the androgen receptors. Current Opinion in Supportive and Palliative Care, 2022, 16, 223-229.	0.5	2
1605	Complexities of Prostate Cancer. International Journal of Molecular Sciences, 2022, 23, 14257.	1.8	20
1606	Optimal Combination of Neuroendocrine Markers for the Detection of High-Grade Neuroendocrine Tumors of the Sinonasal Tract and Lung. Current Oncology Reports, 0, , .	1.8	1
1607	Prostate Cancer Treatment-Related Toxicity: Comparison between 3D-Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) Techniques. Journal of Clinical Medicine, 2022, 11, 6913.	1.0	1
1608	Exploring new frontiers in prostate cancer research:ÂReport from the 2022 Coffeyâ˜Holden prostate cancer academy meeting. Prostate, 2023, 83, 207-226.	1.2	0
1609	Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer. Cancers, 2022, 14, 5922.	1.7	2
1610	Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine. Prostate Cancer and Prostatic Diseases, 2023, 26, 655-664.	2.0	10
1611	Exome sequencing of affected duos and trios uncovers PRUNE2 as a novel prostate cancer predisposition gene. British Journal of Cancer, 0, , .	2.9	2
1612	Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment. Journal of Medicinal Chemistry, 2022, 65, 16099-16127.	2.9	9
1613	Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2023, 26, 194-200.	2.0	8
1614	Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer. Oncologist, 2023, 28, 366-e224.	1.9	1
1615	Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report. Frontiers in Oncology, 0, 12, .	1.3	1

#	Article	IF	Citations
1616	Examining the Effect of PARP-1 Inhibitors on Transcriptional Activity of Androgen Receptor in Prostate Cancer Cells. Methods in Molecular Biology, 2023, , 329-335.	0.4	2
1617	Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors. Journal of Immunotherapy and Precision Oncology, 2023, 6, 31-49.	0.6	1
1618	Molecular Targeted Therapy in Oncology Focusing on DNA Repair Mechanisms. Archives of Medical Research, 2022, 53, 807-817.	1.5	1
1619	Cell-free DNA in the management of prostate cancer: Current status and future prospective. Asian Journal of Urology, 2022, , .	0.5	0
1620	Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy. Neurospine, 2022, 19, 978-993.	1.1	3
1621	ATM suppresses c-Myc overexpression in the mammary epithelium in response to estrogen. Cell Reports, 2023, 42, 111909.	2.9	2
1622	Emerging roles and potential application of PIWI-interacting RNA in urological tumors. Frontiers in Endocrinology, 0, 13, .	1.5	2
1624	Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology, 2023, 20, 205-216.	1.9	10
1625	BRCA Gene Mutations and Prostate Cancer. , 0, , .		0
1626	CHD1, a multifaceted epigenetic remodeler in prostate cancer. Frontiers in Oncology, 0, 13, .	1.3	1
1627	Preclinical patientâ€derived modeling of castrationâ€resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease. Molecular Oncology, 2023, 17, 1129-1147.	2.1	1
1628	DNA repair deficiency as circulating biomarker in prostate cancer. Frontiers in Oncology, 0, 13, .	1.3	8
1630	Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review. World Journal of Men?s Health, 2023, 41, 769.	1.7	10
1631	Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer. International Review of Cell and Molecular Biology, 2023, , 173-210.	1.6	0
1632	Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report. World Journal of Surgical Oncology, 2023, 21, .	0.8	1
1633	Histone methyltransferase KMT2D promotes prostate cancer progression through paracrine IL-6 signaling. Biochemical and Biophysical Research Communications, 2023, 655, 35-43.	1.0	3
1634	Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis. Expert Review of Anticancer Therapy, 2023, 23, 207-216.	1.1	2
1635	Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer. Cell Reports Medicine, 2023, 4, 100937.	3.3	11

#	Article	IF	Citations
1636	Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency. Genomics, Proteomics and Bioinformatics, 2023, , .	3.0	2
1637	Prostate cancer and novel pharmacological treatment optionsâ€“whatâ€™s new for 2022?. Expert Review of Clinical Pharmacology, 2023, 16, 231-244.	1.3	1
1638	miR-29a-5p modulates ferroptosis by targeting ferritin heavy chain FTH1 in prostate cancer. Biochemical and Biophysical Research Communications, 2023, 652, 6-13.	1.0	4
1639	Prognostic value of genomic mutations in metastatic prostate cancer. Heliyon, 2023, 9, e13827.	1.4	3
1640	Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer. Cancers, 2023, 15, 1299.	1.7	5
1641	Bridging Health Disparities: a Genomics and Transcriptomics Analysis by Race in Prostate Cancer. Journal of Racial and Ethnic Health Disparities, 2024, 11, 492-504.	1.8	0
1642	Prospective role of 3Î²HSD1 in prostate cancer precision medicine. Prostate, 2023, 83, 619-627.	1.2	1
1643	Proteomics: A modern tool for identifying therapeutic targets in different types of carcinomas. , 2023, , 333-362.		0
1644	Role of bromodomain and extraterminal (BET) proteins in prostate cancer. Expert Opinion on Investigational Drugs, 2023, 32, 213-228.	1.9	3
1645	Urinary DNA as a Tool for Germline and Somatic Mutation Detection in Castration-Resistant Prostate Cancer Patients. Biomedicines, 2023, 11, 761.	1.4	2
1646	Molecular predictors of metastasis in patients with prostate cancer. Expert Review of Molecular Diagnostics, 2023, 23, 199-215.	1.5	2
1647	Progression in immunotherapy for advanced prostate cancer. Frontiers in Oncology, 0, 13, .	1.3	3
1648	Personalized Systemic Therapies in Hereditary Cancer Syndromes. Genes, 2023, 14, 684.	1.0	4
1649	A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes. Npj Precision Oncology, 2023, 7, .	2.3	3
1650	Matching BRCA and prostate cancer in a public health system: Report of the Italian Society for Uro-Oncology (SIUrO) consensus project. Critical Reviews in Oncology/Hematology, 2023, 184, 103959.	2.0	0
1651	Tumor testing and treatment patterns in veterans with metastatic castration-resistant prostate cancer. Seminars in Oncology, 2023, 50, 11-24.	0.8	0
1652	Advances in PARP Inhibitors for Prostate Cancer. Cancers, 2023, 15, 1849.	1.7	10
1653	Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel. Journal of Molecular Diagnostics, 2023, 25, 295-310.	1.2	1

#	Article	IF	Citations
1654	A study of somatic BRCA variants and their putative effect on protein properties in malignant mesothelioma. Pleura and Peritoneum, 2023, 8, 19-25.	0.5	0
1655	Mechanism of PARP inhibitor resistance and potential overcoming strategies. Genes and Diseases, 2024, 11, 306-320.	1.5	7
1657	Targeting <scp>BRCAâ€mutant</scp> biliary tract cancer: Current evidence and future perspectives. Journal of Digestive Diseases, 2023, 24, 85-97.	0.7	3
1658	Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients. Frontiers in Oncology, 0, 13, .	1.3	0
1659	An approach to genetic testing in patients with metastatic castration-resistant prostate cancer in Singapore. Annals of the Academy of Medicine, Singapore, 2023, 52, 135-148.	0.2	1
1661	Personalised Management of Prostate Cancer. European Medical Journal Urology, 0, , 67-73.	0.0	0
1662	An institutional review of genomic sequencing in pediatric solid tumors. Pediatric Blood and Cancer, 0, , .	0.8	0
1663	Immunotherapy in Prostate Cancer: Recent Advances and Future Directions. European Medical Journal Urology, 0, , 51-61.	0.0	5
1665	Recent advances in targeted therapy for pancreatic adenocarcinoma. World Journal of Gastrointestinal Oncology, 0, 15, 571-595.	0.8	10
1666	The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers. International Journal of Molecular Sciences, 2023, 24, 7293.	1.8	2
1667	Radiotheranostics in advanced prostate cancer: Current and future directions. Prostate Cancer and Prostatic Diseases, 2024, 27, 11-21.	2.0	1
1668	PARP Inhibitors in Breast and Ovarian Cancer. Cancers, 2023, 15, 2357.	1.7	9
1669	PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. European Urology, 2023, 84, 253-256.	0.9	8
1712	A new wave of innovations within the DNA damage response. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	6
1728	SIUrO best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 0, , .	1.4	1
1731	Pathology and Staging. , 2023, , 209-227.		0
1737	Novel treatment strategies to overcome resistance in prostate cancer. , 2024, , 289-308.		0
1738	Overcoming resistance in prostate cancer with targeted and small molecule-based therapies. , 2024, , 255-287.		0

#	Article	IF	Citations
1742	Genetic and biological drivers of prostate cancer disparities in Black men. Nature Reviews Urology, 0, , .	1.9	2
1745	Epigenetic changes driving therapy resistance in prostate cancer. , 2024, , 85-106.		0
1753	Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer. Cancer Treatment and Research, 2023, , 103-124.	0.2	0
1754	Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis. Targeted Oncology, 0, , .	1.7	1
1759	ROS, Redox Regulation, and Anticancer Therapy. , 2023, , 311-409.		0
1760	Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer. Nature Reviews Urology, 0, , .	1.9	0
1773	Rationally Designed DNA-Based Scaffolds and Switching Probes for Protein Sensing. Advances in Biochemical Engineering/Biotechnology, 2023, , .	0.6	0
1794	Pharmacogenomics and Precision Therapy in Prostate Cancer: Challenges and Perspectives. , 2024, , 335-377.		0